Transplantation of an individual's own tissue from one site to another site.
The transference of a part of or an entire liver from one human or animal to another.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The transference of a kidney from one human or animal to another.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transference of a heart from one human or animal to another.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
The transference of either one or both of the lungs from one human or animal to another.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Transference of an organ between individuals of the same species or between individuals of different species.
Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed)
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
The transference of a pancreas from one human or animal to another.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Elements of limited time intervals, contributing to particular results or situations.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The return of a sign, symptom, or disease after a remission.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Transference of fetal tissue between individuals of the same species or between individuals of different species.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Transplantation between animals of different species.
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Prospective patient listings for appointments or treatments.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Partial or total replacement of the CORNEA from one human or animal to another.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
A dead body, usually a human body.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Progenitor cells from which all blood cells derive.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Transference of brain tissue, either from a fetus or from a born individual, between individuals of the same species or between individuals of different species.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Pathological processes of the LIVER.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
The transference between individuals of the entire face or major facial structures. In addition to the skin and cartilaginous tissue (CARTILAGE), it may include muscle and bone as well.
The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Disease having a short and relatively severe course.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
The period following a surgical operation.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Antibodies produced by a single clone of cells.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
The transference of a complete HAND, as a composite of many tissue types, from one individual to another.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A general term for various neoplastic diseases of the lymphoid tissue.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The grafting of bone from a donor site to a recipient site.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
Disorders of the blood and blood forming tissues.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A state of prolonged irreversible cessation of all brain activity, including lower brain stem function with the complete absence of voluntary movements, responses to stimuli, brain stem reflexes, and spontaneous respirations. Reversible conditions which mimic this clinical state (e.g., sedative overdose, hypothermia, etc.) are excluded prior to making the determination of brain death. (From Adams et al., Principles of Neurology, 6th ed, pp348-9)
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
Immunological rejection of leukemia cells following bone marrow transplantation.
Methods for maintaining or growing CELLS in vitro.
Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
The physiological renewal, repair, or replacement of tissue.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Tumors or cancer of the LIVER.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens.
The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed)
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
The chilling of a tissue or organ during decreased BLOOD perfusion or in the absence of blood supply. Cold ischemia time during ORGAN TRANSPLANTATION begins when the organ is cooled with a cold perfusion solution after ORGAN PROCUREMENT surgery, and ends after the tissue reaches physiological temperature during implantation procedures.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Generating tissue in vitro for clinical applications, such as replacing wounded tissues or impaired organs. The use of TISSUE SCAFFOLDING enables the generation of complex multi-layered tissues and tissue structures.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
Excision of all or part of the liver. (Dorland, 28th ed)
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
An individual that contains cell populations derived from different zygotes.
A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (1/3859)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. (2/3859)

Intensive chemotherapy given in early chronic phase of chronic myelogenous leukemia (CML) has resulted in high numbers of circulating Philadelphia (Ph) chromosome-negative hematopoietic progenitor cells (HPC). We have autografted 30 consecutive patients with CML in chronic phase with HPC collected in this way to facilitate restoration of Ph-negative hematopoiesis in bone marrow after high-dose therapy. Hematopoietic recovery to greater than 0.5 x10(9)/L neutrophils and to greater than 25 x 10(9)/L platelets occurred in all patients, a median of 13 (range, 9 to 32) days and 16 (range, 6 to 106) days postautograft, respectively. Regenerating marrow cells were Ph-negative in 16 (53%) patients and greater than 66% Ph-negative in 10 (33%) patients. Twenty-eight patients are alive 6 to 76 months (median, 24 months) after autografting. Three patients have developed blast crisis from which 2 have died. Eight patients are in complete cytogenetic remission at a median of 20 (range, 6 to 44) months with a median ratio BCR-ABL/ABL of 0.002 (range, <0.001 to 0.01). Eight patients are in major cytogenetic remission at a median of 22 (range, 6 to 48) months. No patient died as a consequence of the treatment. All patients had some degree of stomatitis that was severe in 15 (50%) patients. Gastrointestinal and hepatic toxicities were observed in about one fourth of patients. Thus, autografting with Ph-negative mobilized HPC can result in prolonged restoration of Ph-negative hematopoiesis for some patients with CML; moreover, most autograft recipients report normal or near normal activity levels, suggesting that this procedure need not to be associated either with prolonged convalescence or with chronic debility.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (3/3859)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (4/3859)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Lymphomatoid granulomatosis following autologous stem cell transplantation. (5/3859)

Lymphomatoid granulomatosis (LYG) is a rare angio-destructive lymphoproliferative disorder (LPD) of uncertain etiology, with prominent pulmonary involvement. Recent studies indicate that LYG is an Epstein-Barr virus (EBV)-associated B cell LPD with large numbers of background reactive T lymphocytes (T cell-rich B cell lymphoma). Although the disease frequently, but not exclusively, occurs in various immunodeficiency states, it has not been reported in association with the transient immunosuppression following autologous bone marrow/peripheral stem cell transplantation (ABM/PSCT). We describe a patient who developed lymphomatoid granulomatosis of the lung approximately 2 weeks after high-dose chemotherapy and autologous peripheral stem cell transplantation for multiple myeloma. Although molecular studies showed no evidence of EBV genome in the biopsy material, the serologic profile with high IgM titers was suggestive of primary EBV infection. Complete radiologic remission occurred following reconstitution of the patient's immune response after a 2-week course of ganciclovir treatment. Despite the apparently low frequency of LPD (both LYG and EBV-associated post-transplant lymphoma) in the ABMT setting, we believe that it should be considered in the differential diagnosis of patients whose clinical course following ABMT is complicated by fevers, in the absence of an identifiable infectious process.  (+info)

Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. (6/3859)

A limited number of patients with adult T cell leukemia/lymphoma (ATL) who received autologous stem cell transplantation (ASCT) have been reported. We report here a case of fatal systemic Candida krusei infection in a female patient with ATL undergoing ASCT. All of the eight patients (including seven patients in the literature) with ATL who received ASCT developed relapse of ATL or death due to ASCT complication, irrespective of subtype or remission state of ATL, source or selection of SCT or conditioning regimen. At present, ASCT appears to provide little benefit for ATL in contrast to that for other types of aggressive non-Hodgkin's lymphoma.  (+info)

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. (7/3859)

A patient with aplastic anemia failed to respond to immunosuppressive therapy and first marrow transplantation (BMT). Recovery of autologous hematopoiesis was rapid following a second stem cell transplant with a non-myeloablative preparatory regimen. The autologous immune response to infectious mononucleosis (IM) 4 weeks post-transplant was normal despite recent and ongoing severe immunosuppression.  (+info)

Advances in therapy of multiple myeloma: lessons from acute leukemia. (8/3859)

This paper traces the lack of progress, until recently, in the treatment of multiple myeloma (MM) to having ignored the principles that led to cure in acute leukemia more than 2 decades ago. Only in the mid-1980s did investigation begin to consider complete remission (CR) a research objective, representing a necessary first step toward cure. The experience with autologous and allogeneic stem cell-supported high-dose therapy is reviewed, demonstrating, in both historically controlled and randomized studies, the validity of the dose-response concept in MM in terms of increased CR rates as well as extended event-free (EFS) and overall survival (OS). Avoidance of hematopoietic stem cell-damaging agents, especially melphalan, nitrosoureas, and ionizing radiation to marrow-containing sites, assures the ability of peripheral stem cell collection of high quality and quantity, providing rapid engraftment so that mortality is well under 5% following high-dose melphalan (200 mg/m2). This treatment can be applied safely to patients even >70 years of age and in the presence of renal failure. Tandem autotransplants after multiregimen induction have yielded CR rates in the 40% range with median durations of EFS and OS of 43 and 62 months, respectively. Certain chromosomal abnormalities (11 and 13; and translocations) represent the dominant adverse prognosticator for EFS and OS, confirmed in over 500 patients including those with prior therapy. Allogeneic transplants, possible in less than 10% of MM patients, are associated with a 50% mortality during the first year and, unfortunately, late relapses; thus, this approach should be reserved for patients with high-risk disease early in their management. A risk-based treatment algorithm that matches a patient's disease risk with the risk of intervention is presently used, followed by bisphosphonate therapy, not only to delay the onset of MM-related bone disease but also to induce tumor cell apoptosis, indirectly or directly, by down-regulation of cytokines with antiapoptotic activities. Although many patients relapse, this author subscribes to his mentor's motto: "Be Prepared for Success!".  (+info)

Patients following autologous stem cell transplantation are more susceptible to chemotherapy induced bone marrow toxicity. In the present study, bone marrow primitive progenitor cells were examined one year following autologous stem cell transplantation and compared with normal bone marrow and mobilized peripheral blood stem cells. Post-transplantation bone marrow contained a significant lower percentage of quiescent cells in the CD34+/CD38low fraction compared to normal bone marrow. In addition, we observed a strongly decreased stem cell/primitive progenitor frequency in post-transplantation CD34+ cells as defined by long-term culture assays. Measurement of the levels of reactive oxygen species by flow cytometry revealed comparable levels in post-transplantation and normal bone marrow CD34+/CD38low cells, while significantly higher levels of reactive oxygen species were observed in CD34+/CD38high cells following autologous stem cell transplantation compared to normal bone marrow. Moreover, ...
TY - JOUR. T1 - Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation. T2 - Extended follow-up of the multicohort single-arm phase II checkmate 205 trial. AU - Armand, Philippe. AU - Engert, Andreas. AU - Younes, Anas. AU - Fanale, Michelle. AU - Santoro, Armando. AU - Zinzani, Pier Luigi. AU - Timmerman, John M.. AU - Collins, Graham P.. AU - Ramchandren, Radhakrishnan. AU - Cohen, Jonathon B.. AU - De Boer, Jan Paul. AU - Kuruvilla, John. AU - Savage, Kerry J.. AU - Trneny, Marek. AU - Shipp, Margaret A.. AU - Kato, Kazunobu. AU - Sumbul, Anne. AU - Farsaci, Benedetto. AU - Ansell, Stephen M.. PY - 2018/5/10. Y1 - 2018/5/10. N2 - Purpose Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT) ...
TY - JOUR. T1 - Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. AU - Mendpara, S. D.. AU - Ustun, C.. AU - Kallab, A. M.. AU - Mazzella, F. M.. AU - Bilodeau, P. A.. AU - Jillella, A. P.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2002/8. Y1 - 2002/8. UR - http://www.scopus.com/inward/record.url?scp=0036676771&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0036676771&partnerID=8YFLogxK. U2 - 10.1038/sj.bmt.1703646. DO - 10.1038/sj.bmt.1703646. M3 - Letter. C2 - 12203144. AN - SCOPUS:0036676771. VL - 30. SP - 259. EP - 260. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. IS - 4. ER - ...
RATIONALE: Drugs used in chemotherapy, such as carboplatin, thiotepa, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Isotretinoin may be effective in preventing recurrence of glioma. It is not yet known which regimen of chemotherapy plus autologous stem cell transplantation with or without isotretinoin is more effective in treating recurrent high-grade glioma.. PURPOSE: This randomized phase III trial is studying high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation to see how well it works compared to high-dose chemotherapy or intermediate-dose chemotherapy followed by autologous stem cell transplantation and isotretinoin in treating young patients with recurrent high-grade glioma. ...
We conducted a pilot study in 20 patients with high-risk or recurrent/refractory non-Hodgkins lymphoma (NHL) using high-dose sequential chemotherapy (HDSC) and autologous hematopoietic cell transplantation (AHCT). After cytoreduction with standard salvage therapy, HDSC/AHCT was administered in 4 phases at 2- to 4-week intervals. Phase 1 consisted of cyclophosphamide 7 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) at 10 microg/kg per day and leukapheresis upon recovery from white blood cell nadir. The hematopoietic cell product was enriched by Percoll gradient separation and purged with a B-cell or T-cell monoclonal antibody panel and complement. Phase 2 consisted of methotrexate 8 g/m2 with leucovorin rescue and vincristine 1.4 mg/m2. Phase 3 was etoposide 2 g/m2 with G-CSF 5 microg/kg per day. In phase 4, the preparative regimen of mitoxantrone 60 mg/m2 and melphalan 180 mg/m2 was administered followed by AHCT. The NHL histologies were diffuse large cell, follicular/diffuse ...
TY - JOUR. T1 - Autologous blood stem cell versus bone marrow transplantation. AU - Korbling, M.. AU - Juttner, C.. AU - Henon, P.. AU - Kessinger, A.. PY - 1992. Y1 - 1992. UR - http://www.scopus.com/inward/record.url?scp=0026752883&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0026752883&partnerID=8YFLogxK. M3 - Article. C2 - 1355683. AN - SCOPUS:0026752883. VL - 10. SP - 144. EP - 148. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. IS - SUPPL. 1. ER - ...
A favourable course of Crohn disease has been observed after allogeneic bone marrow transplantation, and there is now mounting evidence that autologous stem cell may be an effective treatment for severe autoimmune diseases. Here, we present the first long-term endoscopic follow-up of a patient with Crohn disease undergoing autologous stem cell transplantation for haematological disease. A 54-year-old woman developed Crohn disease and was submitted to ileocaecal resection. Four months after surgery, the patient contracted acute myeloid leukaemia. She was initially treated with chemotherapy, and subsequently underwent autologous stem cell transplantation. Following transplantation, the patient has remained in clinical remission regarding both diseases, without anti-inflammatory medication. She has undergone ileo-colonoscopy with normal findings at 1, 2, 3 and 5 years after transplantation. This case suggests that autologous stem cell transplantation can change not only the clinical course, but ...
Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. Platelet recovery is defined as that day the subject achieves a post-nadir platelet count of ≥20 x 109/L with no platelet transfusion in the prior 7 days ...
High-dose chemotherapy and autologous stem cell transplantation involves the administration of high doses of anti-cancer drugs and/or radiation therapy for the purpose of killing cancer cells, followed by the infusion of stem cells to rescue or restore bone marrow blood cell production. It is important to understand that high-dose chemotherapy is the treatment for your cancer and damage to the bone marrow is a side effect. Fortunately, the bone marrow can be rescued or replaced with stem cells. For autologous stem cell transplantation, stem cells are collected from the patient before high-dose chemotherapy is delivered. The stem cells are collected form the bone marrow or peripheral blood, processed, frozen and stored. Since these cells are collected from the patient, they are referred to as autologous stem cells and the term autologous stem cell transplantation refers to either bone marrow or peripheral blood stem cell transplantation.. High-dose chemotherapy and autologous stem cell ...
Minimal residual disease (MRD) is a powerful determinant of overall outcome in multiple myeloma (MM). Previous studies have demonstrated that the presence of MRD at the traditional day 100 assessment point following autologous stem cell transplant (ASCT) independently predicts for both progression-free (PFS) and overall survival (OS). This effect on outcome is demonstrable in patients achieving a complete response (CR) and in those with both high-risk and standard-risk cytogenetics.1-4 As a consequence, MRD assessment is currently being considered as a surrogate end point for survival in academic clinical trials and for regulatory drug approval.5,6 Surrogate end points are clearly desirable in MM given the increasing complexity of treatment schedules and continually improving complete response rates and survival, such that trials of up-front therapy require 5-10 years of follow up in order to demonstrate survival differences. Acceptance of MRD as an appropriate end point would also ideally ...
As you know, autologous stem cell transplantation remains one of the most effective ways to treat myeloma. Any what we call transplant eligible patient who is fit enough, with not too much comorbidity, should get at some point an autologous stem cell transplantation. That remains true even though we have outstanding new drugs, new proteasome inhibitors, new IMiDs and combinations giving, indeed, excellent results. But still today, and that has been shown with numerous phase III trials comparing an upfront transplant versus a delayed one, every time the upfront transplant, autologous stem cell transplant, was superior and actually the very last trial was performed by the IFM in collaboration with the DFCI, the Americans, this is impress actually and the patients very briefly got VRD, Velcade Revlimid dex, and upfront transplant versus a delayed one at relapse and the option of upfront transplant was largely superior to the delayed one.. Now, even though we are improving myeloma treatment, relapse ...
After autologous hematopoietic cell transplantation (HCT) in the first complete remission (CR1), patients with acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in the second complete remission (CR2). The aim of this study was to analyze the outcome of allogeneic HCT performed in CR2 comparing patients with prior consolidation by autologous HCT versus patients with chemotherapy consolidation. Included were 2619 adults with allogeneic HCT in CR2 from 2000 to 2017 with (n = 417) or without (n = 2202) prior autologous HCT. Patient groups were not entirely comparable; patients with prior autologous HCT were younger, had less often a favorable cytogenetic profile, had more commonly donors other than matched siblings, and more often received reduced-intensity conditioning. In multivariate analysis, nonrelapse mortality risks in patients with prior autologous HCT were 1.34 (1.07 to 1.67; P =.01) after adjustment for age, cytogenetic risk, transplant year, donor, conditioning ...
Bone marrow transplantation, 1993; 11 (1) doi:. Authors: Hardingham J E, Kotasek D, Sage R E, Dobrovic A, Gooley T Hardingham J E, Kotasek D, Sage R E, Dobrovic A, Gooley T, Dale B M et al.(1) Affiliation: Queen Elizabeth Hospital, Woodville Australia Sample size: 10 Abstract: Twenty-seven patients with non-Hodgkins lymphoma (NHL) have undergone peripheral blood stem cell (PBSC) harvesting for autologous transplantation (Tx). A molecular marker was found at presentation in 23/27 patients. Immunoglobulin heavy chain (IgH) or T cell receptor beta (TCR beta) rearrangements were detected by Southern blotting or the polymerase chain reaction (PCR) in 13 patients; PCR detected the bcl-2/JH fusion in 10 patients. Fifteen autologous PBSC transplants have been performed in 11 patients. In 5/11 patients, the marker was present in at least one PBSC collection (in four patients, every PBSC collection was positive). Survival data are available for nine patients (two early deaths); three patients relapsed ...
Background: First-generation autologous chondrocyte implantation has limitations, and introducing new effective cell sources can improve cartilage repair. Purpose: This study was conducted to compare the clinical outcomes of patients treated with first-generation autologous chondrocyte implantation to patients treated with autologous bone marrow-derived mesenchymal stem cells (BMSCs). Study Design: Cohort study; Level of evidence, 3. Methods: Seventy-two matched (lesion site and age) patients underwent cartilage repair using chondrocytes (n = 36) or BMSCs (n = 36). Clinical outcomes were measured before operation and 3, 6, 9, 12, 18, and 24 months after operation using the International Cartilage Repair Society (ICRS) Cartilage Injury Evaluation Package, which included questions from the Short-Form Health Survey, International Knee Documentation Committee (IKDC) subjective knee evaluation form, Lysholm knee scale, and Tegner activity level scale. Results: There was significant improvement in the ...
TY - JOUR. T1 - Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury.. AU - Bedi, Supinder S.. AU - Walker, Peter A.. AU - Shah, Shinil K.. AU - Jimenez, Fernando. AU - Thomas, Chelsea. AU - Smith, Philippa. AU - Hetz, Robert A.. AU - Xue, Hasen. AU - Pati, Shibani. AU - Dash, Pramod K.. AU - Cox, Charles S.. PY - 2013/1/1. Y1 - 2013/1/1. N2 - Autologous bone marrow-derived mononuclear cells (AMNCs) have shown therapeutic promise for central nervous system insults such as stroke and traumatic brain injury (TBI). We hypothesized that intravenous injection of AMNC provides neuroprotection, which leads to cognitive improvement after TBI. A controlled cortical impact (CCI) rodent TBI model was used to examine blood-brain barrier (BBB) permeability, neuronal and glial apoptosis, as well as cognitive behavior. Two groups of rats underwent CCI with AMNC treatment (CCI-autologous) or without AMNC ...
Sarcoma is a peer-reviewed, Open Access journal dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposis sarcoma, are published as well as preclinical and animal studies.
Objectives: The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. However, different reimbursement criteria have been applied in different countries to select patients eligible for treatment with plerixafor. The objective of this observational study was to describe the plerixafor prescription modalities in daily practice in Belgium. Methods: This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkins and non-Hodgkins lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with plerixafor were excluded from the study. Results: The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield > 2 x ...
Autologous stem cell transplant harvests your own stem cells from your body, stores them and injects them back into your body following another potentially harmful treatment like, chemotherapy or radiation. The stem cells are collected through a process called Bone Marrow Aspiration. International Healthcare Providers can guide you through the minefield of researching and selecting a healthcare solution tailored to your needs. We will work with you at every stage to help you better understand the current state of the research and offer you peace of mind, comfort, and security.. You have choices and control when it comes to taking care of your health. International Healthcare Providers can bring you premium access to the best healthcare in North America and help you find a specialist who will walk you through an autologous stem cell transplant.. Autologous stem cell transplants are used in the treatment of a variety of cancers as well as treating musculoskeletal issues. If you think this ...
Autologous stem cell transplantation for the treatment of neuroblastoma in Korea.: Autologous stem cell transplantation (ASCT) for the treatment of high-risk ne
Background. The role of single vs double autologous stem cell transplantation (ASCT) for newly diagnosed (ND) multiple myeloma (MM) continues to be debated in the novel agent era. Methods. The phase III EMN02/HO95 study was designed to administer 3-4 cycles of bortezomib-cyclophosphamide-dexamethasone as induction therapy for NDMM and afterwards to randomize eligible patients to receive (randomization 1, R1) standard-dose intensification treatment with bortezomib-melphalan-prednisone (VMP) for four 42-day cycles or high-dose intensification treatment with melphalan at 200 mg/m2 (HDM) plus ASCT. A second randomization to receive or not receive consolidation therapy was planned after the intensification phase, followed by lenalidomide maintenance in both arms. In centers committed to a double ASCT policy, patients were randomized (1:1:1) to receive VMP or single ASCT (ASCT-1) or two sequential courses of HDM (administered 2 to 3 months apart) plus double ASCT (ASCT-2) in order to prospectively ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The prognosis of brain tumors in children has improved for the last 2-3 decades. However, the prognosis remains dismal in patients with relapsed tumors. The outcome for infants and young children is also poor. For younger children, the ability to use of radiotherapy (RT) is very limited because of the unacceptable long-term adverse effects of RT. The prognosis is also not satisfactory when a large residual tumor remains after surgery or when leptomeningeal seeding is present at diagnosis. In this context, a strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) has been explored to improve the prognosis of recurrent or high-risk brain tumors. It was found that at least some patients with relapsed tumors can be salvaged with HDCT/autoSCT. For infants and young children, it was possible to avoid or defer RT until 3 years of age while maintaining or improving survival rates. Investigators also have explored the efficacy of HDCT/autoSCT in patients with newly ...
TY - JOUR. T1 - Progenitor and lymphoma cells in blood stem cell harvests. T2 - Impact on survival following transplantation. AU - Demirkazik, A.. AU - Kessinger, A.. AU - Armitage, J. O.. AU - Bierman, P. J.. AU - Lynch, J.. AU - Vose, J.. AU - Chan, W.. AU - Sharp, J. G.. PY - 2001. Y1 - 2001. N2 - This study evaluated whether cytokine-induced blood stem cell mobilization also mobilized lymphoma cells and whether lymphoma cell mobilization affected outcome post autologous blood stem cell transplant. Blood stem cell collections from 26 non-Hodgkins lymphoma (NHL) patients harvested during steady-state (non-mobilized) and from 35 NHL patients harvested after cytokine administration (mobilized) were studied. The harvests were cultured and molecularly evaluated for clonal markers of the primary lymphoma. All patients underwent high-dose chemotherapy and autologous transplantation. Graft products from mobilized patients were more likely to contain lymphoma than graft products from non-mobilized ...
TY - JOUR. T1 - Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. T2 - The LateTIME randomized trial. AU - Traverse, Jay H.. AU - Henry, Timothy D.. AU - Ellis, Stephen G.. AU - Pepine, Carl J.. AU - Willerson, James T.. AU - Zhao, David X.M.. AU - Forder, John R.. AU - Byrne, Barry J.. AU - Hatzopoulos, Antonis K.. AU - Penn, Marc S.. AU - Perin, Emerson C.. AU - Baran, Kenneth W.. AU - Chambers, Jeffrey. AU - Lambert, Charles. AU - Raveendran, Ganesh. AU - Simon, Daniel I.. AU - Vaughan, Douglas E.. AU - Simpson, Lara M.. AU - Gee, Adrian P.. AU - Taylor, Doris A.. AU - Cogle, Christopher R.. AU - Thomas, James D.. AU - Silva, Guilherme V.. AU - Jorgenson, Beth C.. AU - Olson, Rachel E.. AU - Bowman, Sherry. AU - Francescon, Judy. AU - Geither, Carrie. AU - Handberg, Eileen. AU - Smith, Deirdre X.. AU - Baraniuk, Sarah. AU - Piller, Linda B.. AU - Loghin, Catalin. AU - Aguilar, ...
TY - JOUR. T1 - Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. AU - de Nigris, Filomena. AU - Williams-Ignarro, Sharon. AU - Sica, Vincenzo. AU - DArmiento, Francesco P.. AU - Lerman, Lilach O.. AU - Byrns, Russell E.. AU - Sica, Giacomo. AU - Fiorito, Carmela. AU - Ignarro, Louis J.. AU - Napoli, Claudio. PY - 2007/4/25. Y1 - 2007/4/25. N2 - Lower-limb ischemia is a major health problem especially when associated to hypercholesterolemia. Because of the absence of effective treatment in the advanced stages of the disease, amputation is undertaken to alleviate unbearable symptoms. Since tissue ischemia and hypercholesterolemia are associated with an overwhelming generation of oxygen radicals, metabolic intervention with antioxidants and l-arginine can induce beneficial effects beyond those achieved by a novel therapeutic approach represented by the use of autologous ...
TY - JOUR. T1 - Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. AU - Rahman, Zia. AU - Kavanagh, John. AU - Champlin, Richard. AU - Giles, Richard. AU - Hanania, Elie. AU - Fu, Siqinq. AU - Zu, Zifei. AU - Mehra, Rakesh. AU - Holmes, Frankie. AU - Kudelka, Andrzej. AU - Claxton, David. AU - Verschraegen, Claire. AU - Gajewski, James. AU - Andreeff, Michael. AU - Heimfeld, Shelly. AU - Berenson, Ronald. AU - Ellerson, Debra. AU - Calvert, Leslie. AU - Mechetner, Eugene. AU - Holzmayer, Tanya. AU - Dayne, Andrew. AU - Hamer, Joy. AU - Bachier, Carlos. AU - Ostrove, Jeffrey. AU - Przepiorka, Donna. AU - Burtness, Barbara. AU - Cote, Richard. AU - Bast, Robert. AU - Hortobagyi, Gabriel. AU - Deisseroth, Albert. PY - 1998/11/1. Y1 - 1998/11/1. N2 - Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic ...
TY - JOUR. T1 - Patients mobilizing large numbers of CD34+ cells (super mobilizers) have improved survival in autologous stem cell transplantation for lymphoid malignancies. AU - Bolwell, B. J.. AU - Pohlman, B.. AU - Rybicki, L.. AU - Sobecks, R.. AU - Dean, R.. AU - Curtis, J.. AU - Andresen, S.. AU - Koo, A.. AU - Mineff, V.. AU - Kalaycio, M.. AU - Sweetenham, J. W.. PY - 2007/9/1. Y1 - 2007/9/1. N2 - The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells (super mobilizers) have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkins lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD3+ cells/kg. ...
Anna J. Kopinska, Grzegorz Helbig, Anna Koclega, Slawomira Kyrcz Krzemien. Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenstr m s Macroglobulinemia. Turk J Hematol. 2017; 34(2): 186- ...
BACKGROUND: Follicular lymphoma (FL) is the most common indolent and second most common Non-Hodgkin`s lymphoma (NHL) in the Western world. Standard treatment usually includes rituximab and chemotherapy. High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is an option for patients in advanced stages or for second-line therapy, leading to improved progression-free survival (PFS) rates. However, the impact of HDT and ASCT remains unclear, as there are hints of an increased risk of second cancers.. OBJECTIVES: We performed a systematic review with meta-analysis of randomised controlled trials (RCTs) comparing HDT plus ASCT with chemotherapy or immuno-chemotherapy in patients with FL with respect to overall survival (OS), PFS, treatment-related mortality (TRM), adverse events and secondary malignancies.. SEARCH METHODS: We searched CENTRAL, MEDLINE, and EMBASE as well as conference proceedings from January 1985 to September 2011 for RCTs. Two review authors independently ...
Autologous stem cell transplants are done using peripheral blood stem cell transplantation (PBSCT). With PBSCT, the stem cells are taken from blood. The growth factor G-CSF may be used to stimulate the growth of new stem cells so they spill over into the blood. G-CSF is a protein that is produced naturally in the body. The blood is removed from a vein and passed through a machine that separates the stem cells. The machine then returns the remaining blood through a needle in the persons arm or through a central venous catheter. This way of collecting stem cells is called apheresis.. In adults, most autologous transplants use stem cells from blood. In a child, the decision whether to use cells from the bone marrow or the blood depends on the size of the child.. ...
Instantly find & access educational materials and complete eLearning activities at your leisure. Native iPad/iPhone/Android Apps are available for the convenience of on-the-go users.
Hematopoietic precursor cells (HPC) are able to restore hematopoiesis after high-dose chemotherapy and their cryopreservation is routinely employed prior to the autologous hematopoietic cell transplantation (AHCT). Although previous studies showed feasibility of long-term HPC storage, concerns remai
Renal impairment (RI) is a negative prognostic factor in Multiple Myeloma (MM) and affected patients are often excluded from autologous stem cell transplantation (ASCT). However, it remains unclear whether historically inferior outcome data still hold true. From a total of 475 eligible MM patients who had undergone ASCT between 1998 and 2016, 374 were included in this multi-centric retrospective cohort study. Renal function was determined both at the time of MM diagnosis and ASCT by estimated glomerular filtration rate (eGFR according to the MDRD formula, RI defined as eGFR | 60 ml/min/1.73m2). Patients were categorized into 3 groups: A) no RI diagnosis and ASCT, B) RI at diagnosis with normalization before ASCT and C) RI both at the time of diagnosis and ASCT. Log-rank testing was used for overall and progression-free survival (OS, PFS) analysis. While severe RI at MM diagnosis confers a risk of shorter OS, MM progression after ASCT is not affected by any stage of renal failure. It can be concluded
The Transplant Committee of the Cancer and Leukemia Group B (CALGB) was organized in the mid-1980s at a time when high-dose chemotherapy with autologous bone marrow transplant was being actively investigated as treatment for a number of solid tumors and hematologic malignancies. Preliminary data from single institution studies had generated considerable interest in the use of high-dose chemotherapy and autologous bone marrow transplant for both metastatic and early-stage high-risk breast cancer, so that such treatment was widely employed at many centers despite the lack of definitive evidence from controlled trials that it was efficacious. Therefore, CALGB designed protocol 9082 to definitively test whether high-dose chemotherapy and autologous bone marrow transplant was superior to intermediate dose chemotherapy in women with stage II breast cancer and ≥10 positive axillary lymph nodes (1).. At the time this trial was initiated, the role of autologous transplantation as treatment for ...
Autologous stem cell transplantation (ASCT) has been employed for patients with relapsed multiple myeloma (MM) after up-front ASCT. The present retrospective study aimed to examine the survival benefit from salvage ASCT. Among 446 patients with relapsed MM after up-front single ASCT, 70 patients rec
Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Autologous transplantation of endothelial progenitor cells (EPCs) is a promising therapeutic approach in the treatment of various vascular diseases. We previously reported a two-step culture system for scalable generation of human EPCs derived from cord blood CD34+ cells ex vivo. Here, we now apply this culture system to expand and differentiate human and nonhuman primate EPCs from mobilized peripheral blood (PB) CD34+ cells for the therapeutic potential of autologous transplantation. The human and nonhuman primate EPCs from mobilized PB CD34+ cells were cultured according to our previously reported system. The generated adherent cells were then characterized by the morphology, surface markers, nitric oxide (NO)/endothelial NO synthase (eNOS) levels and Dil-acetylated low-density lipoprotein (Dil-Ac-LDL) uptake/fluorescein isothiocyanate (FITC)-lectin binding actives. Furthermore, the efficacy and safety studies were performed by autologous transplantation via hepatic portal vein injection in a nonhuman
definition of ABMR, what does ABMR mean?, meaning of ABMR, Autologous Bone Marrow Reinfusion, ABMR stands for Autologous Bone Marrow Reinfusion
Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).. ...
TY - JOUR. T1 - Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. AU - Kozuka, Teruhiko. AU - Kiura, Katsuyuki. AU - Katayama, Hideki. AU - Fujii, Nobuharu. AU - Ishimaru, Fumihiko. AU - Ikeda, Kazuma. AU - Ueoka, Hiroshi. AU - Hamasaki, Shuuji. AU - Yoshino, Tadashi. AU - Kashihara, Yoshio. AU - Date, Hiroshi. AU - Tanimoto, Mitsune. AU - Harada, Mine. PY - 2002/9. Y1 - 2002/9. N2 - Background: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established. Case Report: We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT). One patient with malignant fibrous histiocytoma recurred with multiple lung metastases. This patient ...
TY - JOUR. T1 - Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children. T2 - A single institution experience. AU - Hoepfner, S.. AU - Haut, Paul. AU - OGorman, M.. AU - Kletzel, M.. PY - 2003/2. Y1 - 2003/2. N2 - In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4 + cells was below normal up to 6 months post-transplant, ...
TY - JOUR. T1 - A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory Non-Hodgkin lymphoma. AU - Srivastava, Shivani. AU - Jones, David. AU - Wood, Lisa L.. AU - Schwartz, Jennifer E.. AU - Nelson, Robert P.. AU - Abonour, Rafat. AU - Secrest, Angie. AU - Cox, Elizabeth. AU - Baute, Jay. AU - Sullivan, Cheryl. AU - Kane, Kathleen. AU - Robertson, Michael J.. AU - Farag, Sherif S.. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Clofarabine has significant single-agent activity in patients with indolent and aggressive non-Hodgkin lymphoma and synergizes with DNA-damaging drugs. Treatment, however, may be associated with severe and prolonged myelosuppression. We conducted a phase I trial to determine the maximum tolerated dose (MTD) of clofarabine in combination with high-dose etoposide and cyclophosphamide followed by autologous peripheral blood stem cell ...
Objectives: To carry out a phase I-II trial to elucidate the feasibility and efficacy of high dose cyclophosphamide (CY) supported by autologous peripheral blood stem cell transplantation (PBSCT) in the treatment of severe and refractory autoimmune disease (AD).. Methods: Peripheral blood stem cells (PBSCs) were mobilised during haematological recovery after relatively high dose CY (2 g/m2) for 2 days, followed by administration of granulocyte colony stimulating factor. After collecting PBSCs-more than 2×106 CD34+ cells/kg-by apheresis, CD34+ cells were immunologically selected and cryopreserved. Eight patients were enrolled-five had systemic sclerosis (SSc) alone, one had SSc with systemic lupus erythematosus, one amyopathic dermatomyositis (ADM), and one Wegeners granulomatosis (WG). All of the patients were treated with high dose CY (50 mg/kg) for 4 days and autologous PBSCT.. Results: Haematopoietic reconstitution was rapid and sustained. Toxicity due to the regimen included various ...
The role of autologous peripheral blood stem cell transplantation (APBSCT) in acute myeloid leukaemia (AML) remains controversial. The current study evaluated the application of APBSCT in a large consecutive series of patients with untreated AML, and compared outcome with a predictive model based on MRC AML10 data. Of 148 evaluable patients, 118 patients entered complete remission (CR) after induction therapy comprising three cycles of daunorubicin, cytosine arabinoside and oral 6-thioguanine. Of these patients, 68 (57%) proceeded to consolidation therapy with two courses of intermediate dose cytosine arabinoside, and stem cell mobilisation, and 40 of these patients (34%) underwent the APBSCT procedure after high dose busulphan conditioning. Harvest quality was the main factor precluding APBSCT. Five-year event-free survival (EFS) in patients who achieved CR was 38% and in APBSCT patients was 57%. There were no transplant-related deaths. No significant differences were demonstrated between ...
BACKGROUND: Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old. DESIGN AND METHODS: We evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of the availability of an HLA-identical sibling donor on an intention-to treat basis. Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. RESULTS:
TY - JOUR. T1 - Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. AU - Sauter, Craig S.. AU - Matasar, Matthew J.. AU - Meikle, Jessica. AU - Schoder, Heiko. AU - Ulaner, Gary A.. AU - Migliacci, Jocelyn C.. AU - Hilden, Patrick. AU - Devlin, Sean M.. AU - Zelenetz, Andrew D.. AU - Moskowitz, Craig. PY - 2015/4/16. Y1 - 2015/4/16. N2 - High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the standard of care for chemosensitive relapsed and refractory diffuse large B-cell lymphoma (rel/ref DLBCL). Interim restaging with functional imaging by positron emission tomography using 18F-deoxyglucose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern criteria. Herein, we evaluated 129 patients with rel/ref DLBCL proceeding to HDT-ASCT, with ST response assessment by FDG-PET according to the contemporary Deauville 5-point scale. At 3 years, patients ...
HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology (ASH) meetings on December 8 at 4:45 p.m. PST, show the concern of additional risk is unfounded. Patients with HIV-associated lymphoma (HAL) who meet standard eligibility criteria should receive an autologous blood stem cell transplant as standard of care or be enrolled in a National Institutes of Health (NIH)-funded clinical trial.. The single-arm, multi-institutional clinical trial-conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in collaboration with the AIDS Malignancy Clinical Trials Consortium (AMC)-followed the progress of 40 patients with treatable HIV-1 infection 15 years of age and ...
The search strategy had the broad aim of the retrieval of all relevant studies. With respect to historical versions of the Cochrane Review,10 we applied two different search strategies and retrieved the same studies with aggregate data but different studies with individual cases data. These results show the substantial difficulty associated with the aim of searching for all published cases. This enterprise appears almost impossible. We adopted the new WHO 2013 classification of STS and made minor modifications to define a clear terminology for the study selection process. The group of NRSTS consists of many subtypes that are difficult to diagnose and separate even today. A considerable number of tumours cannot be clearly assigned to a specific histological category. Thus, we may have tumours with a specific label that might not be true. Otherwise, we may have tumours without a specific label that might belong to a specific category. We excluded studies if the proportion of non-eligible ...
Autologous Hematopoietic Stem Cell Transplantation in 48 Patients With End-Stage Chronic Liver Diseases The only presently viable treatment for end-st...
http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1034-4810&volume=33 &issue=Suppl. 1&spage=S154&epage=&date=1997&atitle=Autologous+peripheral+blood+stem+cell+(PBSC)+transplantation+after+megatherapy+for+paediatric+patients+with+high+risk+malignancy:+a+feasible+ ...
Looking for online definition of autotransplants in the Medical Dictionary? autotransplants explanation free. What is autotransplants? Meaning of autotransplants medical term. What does autotransplants mean?
New data supports the safety and efficacy of GSKs Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
Results The median Inflammatory Neuropathy Cause and Treatment (INCAT) score within 1 month prior to AHSCT was 6 and the Rankin score 4. Total INCAT and Rankin scores improved significantly within 2-6 months after AHSCT and continued to do so at last follow-up. The motor action potential amplitudes (CMAP) improved already within 4 months (median) after AHSCT. Three of the 11 patients relapsed during the follow-up period, requiring retransplantation with AHSCT in one. Eight of the 11 patients maintained drug-free remission upon last follow-up. AHSCT was safe but on the short term associated with a risk of cytomegalovirus (CMV) and Epstein-Barr virus reactivation, CMV disease, haemorrhagic cystitis and pancreatitis.. ...
Intensive chemoradiotherapy, with or without additional local radiotherapy, and unpurged autologous marrow transplantation was given to 68 patients with progressive non-Hodgkins lymphoma. Responses were attained in 44 patients (65%, 95% confidence intervals [CI], 52% to 76%), including 37 who achieved complete responses. Fifteen patients (22%, 95% C.I. 13% to 34%) remain free of disease (including 11 continuously) at a median of 5.3 (range 3.1 to 9.1) years later. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and the absence of a history of prior radiotherapy (P = .02, chi 2 test) were associated with achievement of complete plus partial responses. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and less resistant disease status at transplantation (P = .04, chi 2 test) were significant when calculations were limited to complete responses. Karnofsky scores were also associated with the probability of freedom from progression (P = .02, log-rank) for responding ...
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you dont have an account you can just enter your email address in the email box below ...
TY - JOUR. T1 - A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. AU - Adkins, Douglas R.. AU - Irvin, Rebecca. AU - Kuhn, John. AU - Boldt, David H.. AU - Roodman, G. David. AU - Salzman, Donna. AU - Freytes, Cesar. AU - Von Hoff, D. D.. AU - LeMaistre, C. F.. PY - 1993/6. Y1 - 1993/6. N2 - Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities. These characteristics suggest a potential role for this drug in bone marrow transplant preparative regimens. To pursue this hypothesis, 16 patients with refractory solid tumors were enrolled in a phase I study of single agent DTIC to determine the dose of DTIC requiring bone marrow reinfusion and to define the dose-limiting toxicity and maximum tolerated dose when given with autologous bone marrow rescue. Pharmacokinetics ...
TY - JOUR. T1 - Autologous bone marrow transplantation for patients with advanced chronic myelogenous leukemia. AU - Nagamura-Inoue, Tokiko. AU - Tojo, Arinobu. AU - Ikebuchi, Kenji. AU - Takahashi, Satoshi. AU - Ogura, Hiromi. AU - Shindoh, Eiichi. AU - Nagamura, Fumitaka. AU - Uemura, Naoki. AU - Watari, Kiyoshi. AU - Irie, Seiji. AU - Setoyama, Misao. AU - Tajika, Kenji. AU - Nakayama, Michihiro. AU - Nagayama, Hitomi. AU - Kobayashi, Yukio. AU - Shirafuji, Naoki. AU - Sato, Noriharu. AU - Okamoto, Shin ichiro. AU - Ozawa, Keiya. AU - Tani, Kenzaburo. AU - Asano, Shigetaka. PY - 1997/12. Y1 - 1997/12. N2 - We report on seven chronic myelogenous leukemia (CML) patients who received autologous bone marrow transplantation (ABMT) using bone marrow (BM) cells while at the chronic phase (CP) under the various treatments. Of the seven patients, four progressed to accelerated phase (AP) in 83-248 weeks after onset and three patients entered blastic crisis (BC) in 84-171 weeks after onset. All ...
In patients with Hodgkin lymphoma who are at risk for disease progression following autologous stem cell transplantation, early consolidation with brentuximab vedotin (Adcetris) post-transplant significantly improved progression-free survival compared with placebo in the phase III AETHERA trial.1 The median progression-free survival was 43 months for the brentuximab-treated group vs 24 months for the placebo group, representing a significant 43% reduction in the risk of disease progression (P = .001).. In my opinion, once this study is published, brentuximab should be the standard of care for patients with the characteristics in this trial: that is, remission duration less than 1 year, extranodal disease, B symptoms, two or more prior salvage therapies, and primary refractory disease, said lead author Craig Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, New York.. Dr. Moskowitz explained that autologous stem cell ...
To the best of our knowledge, this is the first report of the use of biosimilar G-CSF for the mobilization of PBSC in children committed to autologous transplantation. Biosimilar G-CSF is a cheaper alternative to originator molecule filgrastim. The patent for filgrastim expired in Europe in 2006 and in the United States in 2013. European Medicines Agency has approved several biosimilar versions, three of which are commercially available.[9] Yet, concerns have been raised in 2011 among hematologists on the use of biosimilar G-CSF in stem cell transplant, until sufficient efficacy and safety data are available.[10] The first report of the use of a biosimilar G-CSF for stem cell mobilization for autologous transplantation was published by Lefrère and colleagues in 2011,[11] in whom 40 patients achieved similar mobilization yield and safety profile to the originator G-CSF. Moreover, the biosimilar G-CSF-mobilized cells were able to rescue the patient following high-dose chemotherapy. Speed of both ...
Background:. NY-ESO-1 and LAGE-1a are cancer-testis antigens that are overexpressed in patients with multiple myeloma (MM), and the incidence of these antigens correlates with tumor proliferation and other high-risk features. Genetically engineered NY-ESO-1 SPEAR (specific peptide enhanced affinity receptor) T-cells (NY-ESO-1c259T cells) recognize the peptide sequence SLLMWITQC expressed by NY-ESO-1 or LAGE-1a in the context of HLA-A*02 presentation. This study evaluated treatment with NY-ESO-1 SPEAR T-cells post-autologous stem cell transplant (ASCT) in patients with advanced MM. Methods:. Eligible patients were HLA-A*02:01, 02:05 or 02:06 positive, with refractory, relapsed or high risk MM associated with one or more adverse cytogenetic abnormalities. Eligible patients tumors also expressed NY-ESO-1 and/or LAGE-1a by qPCR. The primary study endpoint was safety. Secondary objectives included overall response rate (ORR) (sCR+CR+VGPR+PR) evaluated with the International Myeloma Working Group ...
Autologous bone marrow or stem cell transplantation has had an important role in the treatment of aggressive lymphoma for several decades. The important results of the PARMA study1 demonstrated that patients in first relapse who remained chemosensitive had improved progression-free and overall survival compared to patients who continued to receive standard-dose salvage therapy. Based on that trial, salvage autologous bone marrow transplantation became the standard of care for these patients and resulted in a long-term progression-free survival rate of approximately 50%.. Consolidation Strategy. If salvage bone marrow transplantation is effective, would consolidation bone marrow transplantation immediately after initial chemotherapy further improve the survival of advanced-stage, aggressive lymphomas? Over the past 2 decades, numerous randomized studies demonstrated no improvement in overall survival when all patients received consolidative autologous bone marrow transplantation or stem cell ...
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with continuous or recurrent symptoms. A 42-year-old male patient with intermittent diarrhe
Brillant C, Skoetz N, Kluge S, Schwarzer G, Trelle S, Greb A, Schulz H, Engert A, Bohlius J. High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD007580. DOI: 10.1002/14651858.CD007580. ...
The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
In this MEDtalk Øivind Fredvik Torkildsen present new data who support, that stem cell transplantation is an effective and relatively safe treatment of MS. ...
Background: The combination of Rituximab and CHOP (R-CHOP) is considered to be the standard treatment for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Treatment results are still unsatisfactory in a significant proportion of patients, particularly in those with a high-risk disease defined by the IPI score. The use of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) is standard clinical practice for patients with relapsed/refractory DLBCL, while its significance as consolidation in first-line treatment remains unclear. Aims: We analyzed safety and effectiveness of R-CHOP followed by salvage chemotherapy and ASCT for patients with young (,65 years) high-risk DLBCL, defined by an age-adjusted IPI score of 2/3, for whom from 2004 on our institutional guidelines recommended ASCT as consolidation. We analyzed prognostic factors in this group. Methods: The treatment program consisted of 4 cycles R-CHOP-14 followed by 3 cycles of a DHAP-like salvage ...
In this retrospective multicentre study, we investigated the outcomes of elderly primary central nervous system lymphoma (PCNSL) patients (greater than or equal to65 years) who underwent high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) at 11 centres between 2003 and 2016. End points included remission, progression-free survival (PFS), overall survival (OS) and treatment-related mortality. We identified 52 patients (median age 68.5 years, median Karnofsky Performance Status before HDT-ASCT 80%) who all underwent thiotepa-based HDT-ASCT. Fifteen patients (28.8%) received HDT-ASCT as first-line treatment and 37 (71.2%) received it as second or subsequent line. Remission status before HDT-ASCT was: CR 34.6%, PR 51.9%, stable disease 3.8% and progressive disease 9.6%. Following completion of HDT-ASCT, 36 patients (69.2%) achieved CR (21.2% first-line setting and 48.1% second or subsequent line setting) and 9 (17.3%) PR (5.8% first-line setting and 11.5% second or subsequent
Clinical trial for Multiple Myeloma , Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen
Limb salvage was possible in all six diabetic patients with Fontaine stage IV CLI following autologous BM MNC injection. The procedure was safe without any adverse outcomes.
The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment. In
Learn more about Other Treatments for Hodgkins Lymphoma: Bone Marrow and Peripheral Stem Cell Transplantation at Doctors Hospital of Augusta Main Page ...
Results Since 2003, 17 pts s-dcSSC were enrolled (4 M, 13 F; median age 40 yrs., ranging 20-62 yrs.), The median follow-up was of 41 months (range 6-136). A beneficial effect was observed in 16/17 pts (94%).The mean mRSS was 20.9 (SD ± 4.0) at baseline (T0), 9.8 (± 4.6) at month 6 (T6), 6.8 (± 2) at month 12 (T12), and 3.0 (± 1.6) at month 60 (T60), (all p,0.001 with respect to T0). The mean ESSG score was 5.2±0.7 at T0, 2.1±0.8 at T6, 2.1±1.8 at T12, and 1.8±0.74 at T60 (all p,0.0001 with respect to T0). OI was nearly unchanged during follow-up. Mean DLCO predicted value was 65.7%±16.8% at T0, 63.2%±12.5% at T12, and 59.8%±16.3% at T60. Mean VC predicted value was 78.7%±22.0% at T0, 83.4%±17.0% at T12, 90.3% ± 26.0% at T60. No echocardiographic changes were identified during follow-up. Two patients died from SSc-related lung and cardiac disease progression, and one patient because of interstitial pneumonia within 100 days after AHSCT, this leading to a TRM of 5.8%.. ...
Heng, B.C.,Phan, T.T.,Liu, H.,Ouyang, H.W.,Cao, T. (2006). Can the therapeutic advantages of allogenic umbilical cord blood-derived stem cells and autologous bone marrow-derived mesenchymal stem cells be combined and synergized?. ASAIO Journal 52 (6) : 611-613. [email protected] Repository. https://doi.org/10.1097/01.mat.0000235330.02549.78 ...
TY - JOUR. T1 - Is there a place for autologous bone marrow transplantation in chronic myeloid leukemia?. AU - Frassoni, F.. AU - Carella, A. M.. PY - 1993. Y1 - 1993. UR - http://www.scopus.com/inward/record.url?scp=0027525235&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0027525235&partnerID=8YFLogxK. M3 - Article. C2 - 8298470. AN - SCOPUS:0027525235. VL - 11. SP - 1. EP - 3. JO - Stem Cells. JF - Stem Cells. SN - 1066-5099. IS - SUPPL. 3. ER - ...
Melphalan at a dose of 200mg/m2 is standard conditioning prior to autologous haematopoietic stem cell transplantation for multiple myeloma, but a dose of 140mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine if melphalan 200 and melphalan 140 are equally effective and tolerable in clinically relevant patient subgroups we analysed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, haematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 (n=245) and melphalan 200 (n=1719) groups ...
9. Bokemeyer C, Franzke A, Hartman JT, et al: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin 25. Dupuis-Girod S, Hartman O, Benhamou E, et al: Will high dose with peripheral blood stem cell support for the treatment of patients chemotherapy followed by autologous bone marrow transplantation with advanced soft tissue sarcomas. Cancer 80:1221-1227, 1997 supplant cranio-spinal irradiation in young children treated for medul- 10. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, 26. Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy autologous bone marrow transplantation, and 13-cis-retinoic acid: and bone marrow rescue for young children with newly diagnosed Childrens Cancer Group. N Engl J Med 341:1165-1173, 1999 malignant brain tumors. J Clin Oncol 16:210-221, 1998 11. Grupp SA, Stern JW, Bunin N, et al: Tandem high-dose therapy 27. Gajjar A, Kuhl J, Epelman S, et al: ...
HIV and AIDS is one of the biggest challenges all over the world. There are an approximately 34 million people living with the virus, and a large number of them become infected each year. Although there are some antiviral drugs for HIV viral load reduction, they are not sufficient. There is no cure for AIDS. Nowadays natural resistance or immunity has absorbed attentions. Because in some HIV positive patients progression trend is slow or even they indicate resistance to AIDS. One of the most interesting approaches in this category is CCR5 gene. CCR5 is a main cc-chemokine co-receptor that facilitates HIV-1 entry to macrophage and CD4(+) T cells. To now, many polymorphisms have been known by CCR5 gene that produces a truncated protein with no function. So, HIV-1 could not entry to immune-cells and the body resistant to HIV/AIDS. Delta 32/Delta 32 and m303/m303 homozygotes are example of mutations that could create this resistance mechanism. There is a new treatment, such as Hematopoietic Stem ...
Most investigators believe that all these new drugs have steadily increased the overall survival substantially, although an accurate number has yet to be established.. With better treatment, the role of autologous stem cell transplantation has been questioned. However, it remains the most potent therapy against myeloma and continues to provide the best odds for achieving complete remission. In fact, a study comparing early autologous stem cell transplant compared to late transplant showed that patients who got the transplant early had longer disease remission, though overall survival was the same. (Attal et al. 2017, 1311-1320) The role of allogeneic therapy remains experimental including the combined use of autologous stem cell transplantation followed by mini allogeneic stem cell transplantation. (Mitsiades et al. 2007, 797-816; Corso and Varettoni 2007, 1-11). Emerging Therapies There are many therapeutics currently being developed for multiple myeloma by a variety of companies.. Anti-CD38 ...
Bobic V (2000). "Autologous chondrocyte transplantation". Medscape. Retrieved 17 September 2008. "Osteochondritis dissecans of ... "Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation". The New England Journal of ... to 9-year outcome after autologous chondrocyte transplantation of the knee". Clinical Orthopaedics and Related Research. 374 ( ... One such technique is autologous chondrocyte implantation (ACI), which is useful for large, isolated femoral defects in younger ...
Agris J. (1987). "Autologous Fat Transplantation: A Three-year Study". American Journal of Cosmetic Surgery. 4 (2): 95-102. doi ... Bircoll M. Autologous Fat Transplantation (presentation) The Asian Congress of Plastic Surgery, February 1982 Bircoll MJ (1984 ... Asken, S. (1987). "Autologous Fat Transplantation: Micro and Macro Techniques". American Journal of Cosmetic Surgery. 4 (2): ... The long-term, volume maintenance data reported in Breast Augmentation using Pre-expansion and Autologous Fat Transplantation: ...
"Autologous Stem Cell Transplantation for Stiff Person Syndrome". JAMA Neurology. 71 (10): 1296-9. doi:10.1001/jamaneurol. ... "Autologous haematopoietic stem cell transplantation for neurological diseases". J Neurol Neurosurg Psychiatry. 89 (2): 147-155 ... Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. Patients with ...
... autologous hematopoietic stem cell transplantation is sometimes performed. The treatment may induce long-term remission even in ... "Autologous haematopoietic stem cell transplantation for neurological diseases". Journal of Neurology, Neurosurgery, and ...
Autologous hematopoietic stem cell transplantation (HSCT) is sometimes used in severe, treatment-refractory MG. Available data ... "Autologous haematopoietic stem cell transplantation for neurological diseases". Journal of Neurology, Neurosurgery & Psychiatry ...
Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ...
This is known as autologous stem cell transplantation. Targeted therapy, which first became available in the late 1990s, has ... For this reason, allogeneic HSCT leads to a higher cure rate than autologous transplantation for several cancer types, although ... Allogeneic hematopoietic stem cell transplantation ("bone marrow transplantation" from a genetically non-identical donor) can ... Damodar, S; Terunuma H; Abraham S (October 2006). "Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid ...
Burman J, Tolf A, Hägglund H, Askmark H (February 2018). "Autologous haematopoietic stem cell transplantation for neurological ... "Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica". Neurology. 93 (18): e1732-e1741 ... Hematopoietic stem cell transplantation (HSCT) is sometimes used in severe cases of NMO. Early data suggested that then- ...
Research to investigate if using high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation was more ... Peinemann F, Enk H, Smith LA (April 2017). "Autologous hematopoietic stem cell transplantation following high-dose chemotherapy ... this is called autologous hematopoietic stem cell transplantation. ...
"A Phase I/II trial of edelfosine purging of autologous bone marrow transplantation (ABMT) in acute leukemia (Meeting abstract ... Vogler, WR; Berdel WE (1993). "Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow". Journal of ...
January 2003). "Autologous bone-marrow stem-cell transplantation for myocardial regeneration". Lancet. 361 (9351): 45-6. doi: ... Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's ... Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... Bone marrow transplantation is, as of 2009, the only established use of stem cells. Hanna V, Gassei K, Orwig KE (2015). "Stem ...
"Micro-Autologous Fat Transplantation for Treating a Gummy Smile". Aesthetic Surgery Journal. doi:10.1093/asj/sjy069. PMC ... and micro-autologous fat transplantation (MAFT). Botox is considered one of the safest and most widely-used injectables. Botox ...
Grigg A, Gibson R, Bardy P, Szer J (1996). "Acute portal vein thrombosis after autologous stem cell transplantation". Bone ... As an adjunct therapy with cyclophosphamide for conditioning prior to bone marrow transplantation in adults and children >12 kg ... Pharmacokinetic and dynamic studies support this use, that has prompted its usage in transplantation regimes, particularly in ... in combination with cyclophosphamide or fludarabine/clofarabine as a conditioning agent prior to bone marrow transplantation, ...
The use of autologous grafts prevents transplantation rejection reactions. Grafts used for oral reconstruction are preferably ... Common approaches for replacing damaged oral mucosa are the use of autologous grafts and cultured epithelial sheets. Autologous ... Other than tissue shortage, donor site morbidity is a common problem that may occur when using autologous grafts. When tissue ...
... hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537. Haller M J ... 2008). "Autologous umbilical cord blood infusion for type 1 diabetes". Exp. Hematol. 36 (6): 710-15. doi:10.1016/j.exphem. ... Cord Blood Hematopoietic Cell Transplantation". In Appelbaum, Frederick R.; Forman, Stephen J.; Negrin, Robert S.; Blume, Karl ... "1956: The First Successful Bone Marrow Transplantation". Australian Cancer Research Foundation. Kaiser LR (1992). "The future ...
July 2009). "Generation and transplantation of an autologous vascularized bioartificial human tissue". Transplantation. 88 (2 ... This imparts an immunologic benefit similar to autologous cell lines (see above). Autologous cells can be considered syngenic, ... ethics of organ transplantation). The same survey as mentioned above shows on the example of autologous cartilage ... Autologous: The donor and the recipient of the cells are the same individual. Cells are harvested, cultured or stored, and then ...
citation needed] Autologous bone marrow transplantation is currently being investigated. Hepatosplenic lymphoma is rare, ... Treatment solely with doxorubicin can make the disease worse.[citation needed] Allogeneic bone marrow transplantation has been ... "Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma". Blood Cancer Journal. 5 (6): e318. doi: ...
... hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537. Haller M J ... The EGE concluded that "[t]he legitimacy of commercial cord blood banks for autologous use should be questioned as they sell a ... 2008). "Autologous umbilical cord blood infusion for type 1 diabetes". Exp. Hematol. 36 (6): 710-715. doi:10.1016/j.exphem. ... Collected cord blood is cryopreserved and then stored in a cord blood bank for future transplantation. Cord blood collection is ...
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250-1260. ...
... patients with cancer undergoing bone marrow transplantation; patients undergoing autologous peripheral blood progenitor cell ... Causes of neutropenia include chemotherapy and bone marrow transplantation. Filgrastim is also used to increase the number of ... hematopoietic stem cells in the blood before collection by leukapheresis for use in hematopoietic stem cell transplantation.[ ...
Boggio L, Pooley R, Winter JN (February 2000). "Typhlitis complicating autologous blood stem cell transplantation for breast ...
October 2009). "Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks". Neurol. Sci. 30 ... October 2010). "Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study". J. ... Scolding N, Marks D, Rice C (February 2008). "Autologous mesenchymal bone marrow stem cells: practical considerations". J. ...
December 2006). "Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient ... Median survival is about 9 months.[citation needed] Autologous stem cell transplantation has been used in treatment. ...
Harel, Adrian (2013-02-13). "Cryopreservation and Cell Banking for Autologous Mesenchymal Stem Cell-Based Therapies". Cell & ... Tissue Transplantation & Therapy. 2013 (5): 1. doi:10.4137/CTTT.S11249. "Cryogenic Storage of Animal Cells". 2010. Retrieved ...
Autologous stem cell transplantation, using the recipient's own cells, is not curative. Younger individuals, if at high risk ... CLL is treated by chemotherapy, radiation therapy, biological therapy, or bone marrow transplantation. Symptoms are sometimes ... An intermediate level, called reduced-intensity conditioning allogeneic stem cell transplantation, may be better tolerated by ... In this case, more aggressive therapies, including lenalidomide, flavopiridol, and bone marrow (stem cell) transplantation, are ...
November 15, 2003). "Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma". ... March 2000). "Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy". Journal of Clinical ... 1998). "CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients". ... January 25, 2007). False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford University Press. pp. 222-223. ISBN ...
"Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia". The Cochrane Database ... In those who have developed critically poor blood flow to the legs, the benefit of autotransplantation of autologous ...
"Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury". Cell Transplantation. 22 (9): ... "Paralyzed man recovers some function following transplantation of OECs and nerve bridge". EurekAlert!. 20 October 2014. Ben ...
... autologous, and allogeneic transplants. Syngeneic transplantations occur between identical twins. Autologous transplantations ... Moreover, autologous strategies generally do not allow for product quality and effectiveness testing prior to transplantation, ... For a long time, bone marrow transplantation was the only clinically applicable method of cell transplantation, however, since ... "Cartilage Repair With Autologous Bone Marrow Mesenchymal Stem Cell Transplantation: Review of Preclinical and Clinical Studies ...
"Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury". Cell Transplantation. 22 (9): ... Transplantation of tissues such as olfactory ensheathing cells from the olfactory bulbs has been shown to produce beneficial ... Use of biomaterials is an engineering approach to SCI treatment that can be combined with stem cell transplantation. They can ... Abraham S (March 2008). "Autologous Stem Cell Injections for Spinal Cord Injury - A multicentric Study with 6 month follow up ...
American Journal of Transplantation. September 2015, 15 (9): 2431-42. PMID 25943855. doi:10.1111/ajt.13288.. ... Successful!) Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. ... The role of peripheral T-cell deletion in transplantation tolerance. Philosophical Transactions of the Royal Society of London ... IL-10 Induces T Cell Exhaustion During Transplantation of Virus Infected Hearts. Cellular Physiology and Biochemistry. 2016, 38 ...
Autologous[edit]. Autologous HSCT requires the extraction (apheresis) of haematopoietic stem cells (HSC) from the patient and ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... 2009). "C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation ... "Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS ...
Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med 248 ... 2006). "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem ... Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and ... "Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a ...
Hair transplantation - a cosmetic procedure practiced by many dermatologists.. *Intralesional treatment - with steroid or ... Vitiligo surgery - Including procedures like autologous melanocyte transplant, suction blister grafting and punch grafting. ...
... or autologous chondrocyte transplantation (ACT). A review evaluating autologous chondrocyte implantation was published in 2010 ... called matrix-associated autologous chondrocyte transplantation (MACT), grows the patient's cells in a 3D matrix of resorbable ... "Autologous chondrocyte transplantation in the treatment of articular cartilage lesions of the talus". Orthopade (in German). ... "Maci" or autologous cultured chondrocytes on porcine collagen membrane, is a treatment to correct cartilage defects in the knee ...
There is also a possibility of fat embolism "associated with liposuction and autologous fat transfer, a procedure where fat ... Penis transplantation. *Sex reassignment surgery. References[edit]. *^ Rashid M, Tamimy MS (2013). "Phalloplasty: The dream and ... Zilg, Brita; Råsten-Almqvist, Petra (2017). "Fatal Fat Embolism After Penis Enlargement by Autologous Fat Transfer: A Case ...
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... "Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a ... "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem Cells 24 (10 ... PMID 17076602. Bone marrow transplantation is, as of 2009, the only established use of stem cells. ...
Autologous stem-cell transplantation using mesenchymal stem cells (MSCs) has been used to improve recovery time from ACL ...
... meaning allogenic or autologous bone marrow cell transplants are necessary. (In autologous BMTs, cells are removed from the ... "Biology of Blood and Marrow Transplantation. 15 (12): 1628-33. PMC 2861656 . PMID 19896087. doi:10.1016/j.bbmt.2009.07.004.. ... In chemotherapy as a conditioning regimen in hematopoietic stem cell transplantation, a study of patients conditioned with ... "Fertility issues following hematopoietic stem cell transplantation". Expert Review of Hematology. 6 (4): 375-388. PMID ...
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a ... Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine". Front ... Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem Cells, 24 ( ...
It appears to be an alternative to the more traditional treatment with melphalan in people who are ill-suited for autologous ... Bone Marrow Transplantation. 24 (12): 1367-8. doi:10.1038/sj.bmt.1702097. PMID 10627651.. ...
Masia J, Pons G, Loschi P, Sanchez Porro-Gil L, Nardulli ML, Olivares L (2015). "Autologous reconstruction of a complex form of ... For heart patients with low cardiac output and who are not candidates for cardiac transplantation, a procedure called ...
Transplantation". 77 (5), s. 762-766, marzec 2004. PMID: 15021844. *↑ D. San Segundo, G. Fernández-Fresnedo, E. Rodrigo, J.C. ... Human T regulatory cells can use the perforin pathway to cause autologous target cell death. „Immunity". 21 (4), s. 589-601, ... Transplantation". 77 (1 Suppl), s. S32-34, styczeń 2004. DOI: 10.1097/01.TP.0000106470.07410.CA. PMID: 14726768. ... Transplantation". 83 (11), s. 1477-1484, czerwiec 2007. DOI: 10.1097/01.tp.0000264997.53153.8b. PMID: 17565321. ...
Rebeiro P, Moore J (2016). "The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune ... Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... "Safety of Autologous Bone Marrow Stromal Cell Transplantation in Dogs with Acute Spinal Cord Injury". Veterinary Surgery. 41 (4 ... based on the creation of a disease-resistant immune system through transplantation of autologous, gene-modified (HIV-1- ...
Face transplantation-fantasy or the future? Lancet 360:5-6; 2002. *^ Shiffman, Melvin (5 September 2012). Cosmetic Surgery: Art ... the patient had a complication and after two days the surgeons had to replace the facial graft with autologous tissue. The ... Outcomes 18 Months after the First Human Partial Face Transplantation, New England Journal of Medicine, 13 December 2007 ... On Face Transplantation: Like and Ethics in Experimental Biomedicine. London: Palgrave Macmillan ...
2009). "Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase ...
"Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation ... "Autologous Multiple Injections of in Vitro Expanded Autologous Bone Marrow Stem Cells For Cervical Level Spinal Cord Injury - A ... Wakitani has published a small case series of nine defects in five knees involving surgical transplantation of mesenchymal stem ... "Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells, platelate ...
Autologous immune enhancement therapy use a person's own peripheral blood-derived natural killer cells, cytotoxic T lymphocytes ... Immunosuppressive drugs help manage organ transplantation and autoimmune disease. Immune responses depend on lymphocyte ... Adoptive cell transfer in vitro cultivates autologous, extracted T cells for later transfusion.[15] ... It has been tested on transplantations, and type 1 diabetes or other autoimmune disorders. ...
In a transplantation model of LMP1-fueled lymphomas, the NKG2D-Fc fusion proved capable of reducing tumor growth and prolonging ... Since NK cells recognize target cells when they express nonself HLA antigens (but not self), autologous (patients' own) NK cell ...
AutologousEdit. Autologous HSCT requires the extraction (apheresis) of haematopoietic stem cells (HSC) from the patient and ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... 2009). "C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation ... Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2 (1): 3-14 ...
Autologous platelet-rich plasma for treating chronic wounds PMID 27223580 https://doi.org/10.1002/14651858.CD006899.pub3 ... Amniotic membrane transplantation for acute ocular burns PMID 22972141 https://doi.org/10.1002/14651858.CD009379.pub2 ... Autologous platelet concentrates for treating periodontal infrabony defects PMID 30484284 https://doi.org/10.1002/14651858. ...
January 2009). "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a ... July 2007). "Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from ... May 2008). "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in ... with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation ...
ಪ್ರಾಚೀನ ಗ್ರೀಸ್ ನಲ್ಲಿ, ರೋಗಗಳನ್ನು ಗುಣಪಡಿಸುವ ದೇವರು ಎನ್ನಲಾದ ಎಸ್ಕ್ಲೆಪ್ಯಸ್ ದೇವಾಲಯಗಳನ್ನು ನಿರ್ಮಿಸಿ ಅರ್ಪಿಸಲಾಗುತ್ತಿತ್ತು, ಇದನ್ನು ಎಸ್ಕ್ಲೆಪಿಯಾ ಎಂದು ಕರೆಯಲಾಗುತ್ತಿತ್ತು(Greek: Ασκληπιεία, ಅಂದರೆ ಸ್ತುತಿಸುವುದು. ಎಸ್ಕ್ಲೆಪಿಯಿಯೊನ್ Ασκληπιείον )ಗಳು ವೈದ್ಯಕೀಯ ಸಲಹೆ, ತಪಾಸಣೆ ಮತ್ತು ಗುಣಪಡಿಸುವ ಸ್ಥಳಗಳಾಗಿ ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿದ್ದವು.[೫] ಇಂತಹ ದೇವಾಲಯಗಳ ಆವರಣಗಳಲ್ಲಿ ಪ್ರವೇಶಿಸಿದ ರೋಗಿಗಳು ಯಾವದೋ ಒಂದು ಕನಸಿನ ಸ್ಥಿತಿಗೆ ಕಾಲಿಟ್ಟು ...
Livebirth after orthotopic transplantation of cryopreserved ovarian tissue[permanent dead link] The Lancet, September 24, 2004 ... Lan C, Xiao W, Xiao-Hui D, Chun-Yan H, Hong-Ling Y (February 2010). "Tissue culture before transplantation of frozen-thawed ... However, none of the fertility restoration options from frozen tissue, i.e. cell suspension transplantation, tissue grafting ... Animal data are promising since healthy offspring have been obtained after transplantation of frozen testicular cell ...
One supposed cure to HIV-1 involves the creation of a disease-resistant immune system through transplantation of autologous, ... Stem cell transplantation[edit]. In 2007, Timothy Ray Brown,[12] a 40-year-old HIV-positive man, also known as "the Berlin ... Schneider, Thomas (2011-03-10). "Evidence for the cure of HIV infection by CCR532/32 stem cell transplantation". Blood. 117 (10 ... This study demonstrated the efficacy of a transplantation approach that ultimately allows for an enriched population of HSPCs ...
Denne artikkelen bygger på «Hematopoietic stem cell transplantation» frå Wikipedia på engelsk, den 8. januar 2015. ... 1999). «Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. ... Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League ...
Transplantation. 85 (9): 1339-47. doi:10.1097/TP.0b013e31816dd64a. PMID 18475193.. *^ de Mare-Bredemeijer EL, Shi XL, Mancham S ... Successful!) Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. ... "Biology of Blood and Marrow Transplantation. 24 (3): 618-622. doi:10.1016/j.bbmt.2017.11.022. PMC 5826878. PMID 29197679.. ... During transplantationEdit. While during infection T cell exhaustion can develop following persistent antigen exposure after ...
... including transplantation of melanocyte precursors derived from hair follicles. Transplantation procedures are frequently used ... Olsson MJ, Juhlin L (2002). "Long-term follow-up of leucoderma patients treated with transplants of autologous cultured ... Olsson MJ, Juhlin L (1992). "Melanocyte transplantation in vitiligo". Lancet. 340 (8825): 981. doi:10.1016/0140-6736(92)92875-G ... The longevity of the repigmentation differed from person to person.[36] To date, several transplantation techniques have been ...
Autologous Fat Transplantation. Dtsch Arztebl Int 2018; 115: 596. DOI: 10.3238/arztebl.2018.0596b ... In this context, intraarticular autologous fat transplantation for the treatment of osteoarthritis of the basal joint of the ... Professor Rennekampff is the guideline coordinator of the S2k guideline on autologous fat transplantation. ... Haas EM, Volkmer E, Giunta RE: Pilot study on the effects and benefits of autologous fat grafting in osteoarthritis of the CMC- ...
In an autologous transplant, your own blood-forming stem cells are collected and stored and then given back to you after ... In autologous transplantation, doctors usually collect, or harvest, stem cells that circulate in the bloodstream. These cells ... Autologous Transplant: A Guide for Patients and Caregivers. Read our guide to autologous stem cell transplants. It helps you ... Blood & Marrow Stem Cell Transplantation More About Blood & Marrow Stem Cell Transplantation ...
Autologous stem-cell transplantation is distinguished from allogenic stem cell transplantation where the donor and the ... Autologous stem-cell transplantation (also called autogenous, autogeneic, or autogenic stem-cell transplantation and ... is autologous transplantation of stem cells-that is, transplantation in which stem cells (undifferentiated cells from which ... Autologous hematopoietic stem-cell transplantation Stem-cell therapy "What Are Stem Cells?". Retrieved 2017-02-12. Mahla RS ( ...
Kumar L, Boya RR, Pai R et al (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J ... Malhotra P, Yanamandra U, Khadwal A et al (2017) Autologous stem cell transplantation for multiple myeloma: single centre ... Prinja S, Kaur G, Malhotra P et al (2017) Cost-effectiveness of autologous stem cell treatment as compared to conventional ... 1.Division of Hematology and Bone Marrow TransplantationMax Superspeciality HospitalNew DelhiIndia ...
We describe the results of a clinical trial to evaluate the feasibility and toxicity of autologous hematopoietic stem cell ... transplantation (auto-HSCT) for patients with progressive multiple sclerosis... ... Multiple sclerosis Autologous hematopoietic stem cell transplantation This is a preview of subscription content, log in to ... Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. 2004;62:282-284.CrossRef ...
... autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple ... Who is most suited to undergo ASCT? Is there an age threshold that should not be surpassed? Should transplantation be embarked ... What is the role of tandem transplantation in the era of novel agents and where do patient-specific cytogenetics come into the ... followed by autologous stem cell transplantation (ASCT)2,3,4, transplantation remains the standard for treating newly diagnosed ...
As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves ... Single versus double autologous stem-cell transplantation for multiple myeloma.. Attal M1, Harousseau JL, Facon T, Guilhot F, ... of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. ... Tandem bone marrow transplantation in multiple myeloma. [N Engl J Med. 2004] ...
Autologous Fibroblast Transplantation in Facial Deformities Official Title ICMJE Autologous Transplantation of Cultured ... Autologous Fibroblast Transplantation in Facial Deformities. The safety and scientific validity of this study is the ... Long-Term Follow-up of Autologous Fibroblast Transplantation for Facial Contour Deformities, A Non-Randomized Phase IIa ... Autologous cultured fibroblast is derived from in vitro expansion of fibroblasts harvested from the patients normal skin. ...
Transplantation of Fibroblast for Correction of Nasolabial Folds. he study evaluated the safety and efficacy of the Autologous ... More From BioPortfolio on "Autologous Fibroblast Transplantation in Facial Deformities". *Related Companies*Related Events* ... Autologous cultured fibroblast is derived from in vitro expansion of fibroblasts harvested from the patients normal skin. ... Correcting Nasojugal Groove with Autologous Cultured Fibroblast Injection: A Pilot Study.. A new commercial drug that contains ...
... Ann Surg. 1995 Oct;222(4):562-75; discussion ... Between 2 and 10 years after transplantation, 34% were insulin independent, with no grafts failing after 2 years. The main ... 2 years after transplantation). In turn, the number of islets recovered correlated with the degree of fibrosis (r = -0.52, p = ...
This surgical procedure replaces damaged cartilage in the knee joint with healthy cartilage cells. These cells are harvested from healthy portions of the knee and are grown in a lab for implantation. This procedure is usually performed in two stages, with two separate surgeries.
... a manual of transplantation technique. [K Draenert; F Baumgaertel; R Aufenberg;] -- Annotation This book describes in detail a ... unique and very precise operative technique that uses autologous cartilage/bone grafts for the reconstruction of load-bearing ... autologous> # Transplantation, Autologous a schema:Intangible ;. schema:name "Transplantation, Autologous"@en ;. . ... Autologous resurfacing and fracture dowelling : a manual of transplantation technique. Author:. K Draenert; F Baumgaertel; R ...
... ... found convincing evidence that autologous (meaning transferred from the same individual) transplantation of cells that ... Lam, however, emphasized that more animal studies need to be performed before EPC transplantation for acute lung injury can be ... "Our results obtained from a rabbit model of acute lung injury showed that transplantation of these premature EPCs significantly ...
... Am J Sports Med. ... Purpose: To investigate in vivo cartilage repair outcome of autologous cartilage chips compared with marrow stimulation in full ... The two treatment groups were (1) autologous cartilage chips embedded in fibrin glue (ACC) (n = 12) and (2) marrow stimulation ...
Researchers evaluate the safety of transplanting autologous Schwann cells into the injury epicenter of subjects with spinal ... Safety of Autologous Human Schwann Cell Transplantation for Spinal Cord Injuries Following Spinal Cord Injury, Schwann Cell ... A Phase I clinical trial was conducted to evaluate the safety of autologous human SC transplantation into the injury epicenter ... For the references and the full article please visit Safety of Autologous Human Schwann Cell Transplantation in Subacute ...
Maintenance Therapy With Rituximab After Autologous Transplantation for Non-Hodgkins Lymphoma. Trial Phase:. Phase 3. Minimum ... Maintenance Therapy With Rituximab After Autologous Transplantation for Non-Hodgkins Lymphoma. Rituxan is a mouse antibody ... post an autologous stem cell transplant and are in CR. Patients who are positive for. t(14;18) by PCR or for BCL-2 by Southern ...
A journal of one persons experience with Autologous Stem Cell Transplantation for multiple sclerosis Though Ive lived on the ... I am participating in a Phase I trial testing the use of autologous stem cell transplantation to cure MS. Results in Europe ... The source of the fever was engraftment syndrome, which is rare in autologous BMT, but has occurred in all the MSers done so ... S-19 EFFICACY OF STEM CELL TRANSPLANTATION IN TREATMENT OF MULTIPLE SCLEROSIS IN EUROPE from Cowboys post of 9/24 titled ...
Experimental: Autologous MSC transplantation Biological: Autologous mesenchymal stem cell transplantation A single IV infusion ... Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS. The safety and scientific validity of this study is the ... A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in ... The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, ...
Autologous Stem Cell Transplantation in Acute Myocardial Infarction. The safety and scientific validity of this study is the ... The primary objective of the ASTAMI study is to test whether intracoronary transplantation of autologous mononuclear bone ... 1 way to either intracoronary transplantation of autologous mBMC 5-8 days after PCI or to control. Left ventricular function, ... Intracoronary transplantation of different cell populations have been used in acute myocardial infarction (AMI) with promising ...
Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Official Title ICMJE Autologous Transplantation of ... Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin. The safety and scientific validity of this study is ... The purpose of this study is to investigate the efficacy and safety of autologous transplantation of melanocytes in patients ... Experimental: cell transplantation group Epidermal Cell transplantation in patients with vitiligo. Intervention: Biological: ...
Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina. Douglas W. Losordo, Richard A. Schatz, ... Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina. Douglas W. Losordo, Richard A. Schatz, ... Intramyocardial Transplantation of Autologous CD34+ Stem Cells for Intractable Angina. A Phase I/IIa Double-Blind, Randomized ... This report details a first-in-human experience with intramyocardial, transendocardial transplantation of autologous CD34+ ...
Keywords : Hodgkins lymphoma; Hematopoietic stem cell transplantation; Autologous transplantation; Doxorubicin; Bleomycynm; ... CORTEZ, Afonso José Pereira et al. Autologous hematopoietic stem cell transplantation in classical Hodgkins lymphoma. Rev. ... CONCLUSION: Autologous hematopoietic stem cell transplantation is an effective treatment strategy for early and late relapse in ... submitted to autologous hematopoietic stem cell transplantation in a single transplant center. METHODS: A retrospective study ...
Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after ... Autologous pancreatic islet cell transplantation involves the removal of parts of the patients own pancreas (the islet cells, ... Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. Interventional procedures ... Scotland and Northern Ireland on autologous pancreatic islet cell transplantation for improved glycaemic control after ...
autologous stem cell transplantation listen (aw-TAH-luh-gus ... tranz-plan-TAY-shun) A procedure in which blood-forming stem ...
Histomorphometric Evaluation of Superovulation Effect on Follicular Development after Autologous Ovarian Transplantation in ... "Histomorphometric Evaluation of Superovulation Effect on Follicular Development after Autologous Ovarian Transplantation in ...
Therefore, primary and secondary follicles can survive after autologous transplantation but their reservations diminished by ... Histomorphometric Evaluation of Superovulation Effect on Follicular Development after Autologous Ovarian Transplantation in ... Angiogenesis was observed after mouse ovarian transplantation on days 14 and 21 after ovarian grafting. After transplantation, ... The effect of superovulation by pregnant mare serum gonadotropin (PMSG) on autologous transplanted ovaries in the lumbar ...
Report on autologous fat transplantation. ASPRS Ad-Hoc Committee on New Procedures, September 30, 1987.. [No authors listed] ...
Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after ... Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. Interventional procedures ...
Advantages and disadvantages of autologous stem cell transplantation. In autologous transplantation, the reinfused stem cells ... "Autologous haematopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation ... Collection of the autologous graft. *What conditions can underlie autologous hematopoietic cell transplantation:*How to decide ... Patients undergoing transplantation are at risk for developing a second cancer. For those undergoing autologous transplantation ...
  • Autologous haematopoietic stem cell transplantation (AHSCT) has been performed as a last treatment resort in a few therapy-refractory cases with CIDP. (bmj.com)
  • Autologous haematopoietic stem cell transplantation (HSCT) with CD34 + cell selection has recently been used in the treatment of refractory Crohn's disease, showing good safety and promising efficacy. (bmj.com)
  • Conversely, autologous haematopoietic stem cell transplantation (AHSCT) has demonstrated to be sometimes an effective treatment in patients (pts) with severe (s) diffuse cutaneous (dc) SSc. (bmj.com)
  • Objectives We conducted a systematic review to compare the efficacy and adverse events of autologous haematopoietic stem cell transplantation (HSCT) following high-dose chemotherapy (HDCT) versus standard-dose chemotherapy (SDCT) in patients with locally advanced or metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). (bmj.com)
  • Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. (diva-portal.org)
  • Autologous haematopoietic stem cell transplantation (HSCT) for Crohn's disease has been described by Oyama and co‐workers as producing remission in 11 of 12 patients with refractory Crohn's disease after a median follow up of 18.5 months. (pubmedcentralcanada.ca)
  • High-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation (AHSCT) is a new and promising approach to multiple sclerosis (MS) treatment. (omicsonline.org)
  • More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. (nature.com)
  • Patients undergo autologous stem cell transplantation (ASCT) on day 0. (bioportfolio.com)
  • Second transplantation: Within 6-12 months after the first ASCT, patients not achieving a complete response receive high-dose melphalan IV over 20 minutes on days -3 and -2 and a second ASCT on day 0. (bioportfolio.com)
  • Several clinical studies have compared single with tandem (also called double) autologous stem cell transplantation (ASCT) as first-line treatment in patients with symptomatic multiple myeloma (MM), one of the leading indications for ASCT worldwide. (cochrane.org)
  • In an attempt to improve the dismal prognosis of adults with recurrent medulloblastoma, six patients were treated with aggressive salvage therapy including high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). (virtualtrials.com)
  • Autologous stem cell transplantation (ASCT) induces long-term drug-free disease remission in patients with juvenile idiopathic arthritis. (sigmaaldrich.com)
  • The role of single vs double autologous stem cell transplantation (ASCT) for newly diagnosed (ND) multiple myeloma (MM) continues to be debated in the novel agent era. (bloodjournal.org)
  • Because myeloablative treatment and transplantation enforce stress on HSCs, we followed 81 patients with solid tumors or lymphoid diseases undergoing autologous stem cell transplantation (ASCT) for the development of CHIP. (fraunhofer.de)
  • Autologous stem cell transplantation (ASCT) improved outcome compared to conventional chemotherapy in newly diagnosed multiple myeloma (NDMM) patients. (linkos.cz)
  • According to the Nordic MCL-2 protocol we prospectively analyzed the efficacy of pre-emptive treatment using rituximab to MCL patients in molecular relapse after autologous stem cell transplantation (ASCT). (lu.se)
  • For multiple myeloma, high-dose chemotherapy and autologous blood stem-cell transplantation (ASCT) followed by lenalidomide maintenance (LenMT) at 10-15 mg/day is considered standard of care. (aacrjournals.org)
  • Here we evaluate the results of high-dose chemotherapy and autologous stem-cell transplantation (HDC/ASCT) in 114 patients included in the GEL/TAMO registry between January 1990 and December 1999 with diffuse large B-cell lymphoma who failed to achieve complete remission (CR) with front-line conventional chemotherapy. (cun.es)
  • High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is supposed to overcome the blood-brain barrier and eliminate residual disease in the CNS. (uni-muenchen.de)
  • We describe the results of a clinical trial to evaluate the feasibility and toxicity of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with progressive multiple sclerosis (MS). Fifteen patients (all patients with secondary progressive MS) were enrolled. (springer.com)
  • Over the last two decades, autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). (frontiersin.org)
  • We also detail immune reconstitution studies that have been integrated into the randomized controlled Autologous Stem cell Transplantation In refractory CD-Low Intensity Therapy Evaluation trial, which is designed to test the hypothesis that auto-HSCT using reduced intensity mobilization and conditioning regimens will be a safe and effective means of inducing sustained control in refractory CD compared to standard of care. (frontiersin.org)
  • Indications for hematopoietic stem cell transplantation (HSCT) have decreased with the improvement in chemotherapy for pediatric acute myeloid leukemia (AML) in the last decade. (unboundmedicine.com)
  • We conducted reevaluation of autologous HSCT (AHSCT) to compare myeloablative conditioning (MAC) regimens for pediatric AML without the need for consideration of toxicities caused by allogeneic immune reactions. (unboundmedicine.com)
  • Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) is potentially curative for several malignancies. (termedia.pl)
  • Graft-versus-host disease (GVHD) in patients who received autologous hematopoietic stem cell transplantation (HSCT) is less common compared to patients who received allogeneic stem cell transplantation. (termedia.pl)
  • We present the case of a 4-year-old girl with metastatic neuroblastoma who spontaneously developed AGVHD after autologous HSCT. (termedia.pl)
  • She was then treated with autologous HSCT. (termedia.pl)
  • Engraftment of neutrophils and platelets took place on day +11 and +14 respectively after autologous HSCT. (termedia.pl)
  • Autologous HSCT with unselected PBSC appears to be safe and can induce and maintain remission in previously refractory Crohn's disease patients. (bmj.com)
  • Overall survival in the RCT was reported not statistically significantly different between autologous HSCT following HDCT versus SDCT. (bmj.com)
  • Conclusions Overall survival in patients with locally advanced or metastatic NRSTS was not statistically different after autologous HSCT following HDCT compared with SDCT in a single RCT with a total of 83 patients. (bmj.com)
  • 1 They postulated that autologous HSCT was useful for refractory Crohn's disease. (pubmedcentralcanada.ca)
  • She developed a KI1 positive anaplastic non‐Hodgkin's lymphoma (NHL) three years later, treated successfully with ablative CHOP chemotherapy and autologous HSCT, inducing remission for the past 12 years (and she remains in remission on no treatment). (pubmedcentralcanada.ca)
  • As a consequence of her autologous HSCT she also went into long term remission from her Crohn's disease, but relapsed after eight years. (pubmedcentralcanada.ca)
  • Our case is the longest reported "follow up" of autologous HSCT in Crohn's disease and raises some interesting questions with regard to the long term efficacy of autologous HSCT for Crohn's disease, as our patient appeared to be in complete long term remission and was apparently "cured" of her Crohn's disease for eight years before relapsing. (pubmedcentralcanada.ca)
  • We postulate that the autologous HSCT led to ablation of "activated" T cells for a prolonged period (resetting the immune system) but that her genetic predisposition (positive family history), allied to other environmental factors (smoking), subsequently led to her disease relapse. (pubmedcentralcanada.ca)
  • This is in keeping with the current hypothesis of the aetiopathogenesis of Crohn's disease and suggests that autologous HSCT will not provide a long term "cure" for this disorder. (pubmedcentralcanada.ca)
  • Should cardiac screening be used to risk stratify patients with systemic sclerosis being considered for hemopoietic stem-cell transplantation (HSCT)? (acc.org)
  • The authors concluded that autologous HSCT with a non-myeloablative regimen of cyclophosphamide and rabbit anti-thymocyte globulin (rATG) with a nonselected autograft results in sustained improvement in skin thickness and forced vital capacity. (acc.org)
  • Autologous stem-cell transplantation (also called autogenous, autogeneic, or autogenic stem-cell transplantation and abbreviated auto-SCT) is autologous transplantation of stem cells-that is, transplantation in which stem cells (undifferentiated cells from which other cell types develop) are removed from a person, stored, and later given back to that same person. (wikipedia.org)
  • Although it is most frequently performed with hematopoietic stem cells (precursors of blood-forming cells) in hematopoietic stem cell transplantation, cardiac cells have also been used successfully to repair damage caused by heart attacks. (wikipedia.org)
  • Autologous stem-cell transplantation is distinguished from allogenic stem cell transplantation where the donor and the recipient of the stem cells are different people. (wikipedia.org)
  • Autologous hematopoietic stem-cell transplantation Stem-cell therapy "What Are Stem Cells? (wikipedia.org)
  • Autologous stem-cell transplantation entry in the public domain NCI Dictionary of Cancer Terms ScienceDaily Report University of Louisville. (wikipedia.org)
  • Kumar L, Boya RR, Pai R et al (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. (springer.com)
  • Malhotra P, Yanamandra U, Khadwal A et al (2017) Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. (springer.com)
  • Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. (springer.com)
  • Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting close to a cure? (springer.com)
  • High-dose immunosup-pression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. (springer.com)
  • Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. (springer.com)
  • Single versus double autologous stem-cell transplantation for multiple myeloma. (nih.gov)
  • As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation. (nih.gov)
  • In contrast to more controversial stem cell transplantation, the new technique employs a subject's own progenitor cells, which are present in adults and are more restricted than stem cells in the type of tissues they can subsequently form. (newswise.com)
  • Cell transplantation is a leading candidate therapy to repair tissue damage in the traumatically injured spinal cord. (genengnews.com)
  • I am participating in a Phase I trial testing the use of autologous stem cell transplantation to cure MS. Results in Europe have been very promising, though not perfect. (mult-sclerosis.org)
  • The study is an investigator-run, open-label Phase 1 safety study of autologous mesenchymal stem cell transplantation, involving approximately 24 ambulatory participants with relapsing forms of MS (approximately equal numbers with relapsing-remitting and secondary progressive/ progressive relapsing MS) and evidence of involvement of the anterior afferent visual system. (clinicaltrials.gov)
  • For this group, hematopoietic stem cell transplantation is considered one option of salvage therapy. (scielo.br)
  • To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered relapse or who were refractory to treatment, submitted to autologous hematopoietic stem cell transplantation in a single transplant center. (scielo.br)
  • Autologous hematopoietic stem cell transplantation is an effective treatment strategy for early and late relapse in classical Hodgkin's lymphoma for cases that were responsive to pre-transplant chemotherapy. (scielo.br)
  • The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. (nice.org.uk)
  • This document together with the guidance published on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (NICE interventional procedure guidance 257) replaces previous guidance on pancreatic islet cell transplantation. (nice.org.uk)
  • Autologous pancreatic islet cell transplantation involves the removal of parts of the patient's own pancreas (the islet cells, which are responsible for insulin production), after the pancreas has been removed. (nice.org.uk)
  • Abnormalities of chromosome (ch)1 have been shown to be significant adverse prognostic factors in multiple myeloma (MM) but they have not yet been systematically studied in patients undergoing autologous hematopoietic cell transplantation (auto-HCT). (omicsonline.org)
  • Autologous hematopoietic cell transplantation (HCT) is the intravenous infusion of hematopoietic stem and progenitor cells designed to re-establish marrow and immune function in patients with a variety of acquired malignant disorders, who are being treated with high dose chemotherapy or chemoradiotherapy to treat the disease. (renalandurologynews.com)
  • Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. (rutgers.edu)
  • Autologous hematopoietic stem cell transplantation (AHSCT) is currently investigated as treatment for severe and refractory autoimmune diseases, such as multiple sclerosis (MS), systemic sclerosis (SSc), Crohn's disease (CD) and systemic lupus erythematosus. (rutgers.edu)
  • Autologous hematopoietic cell transplantation (auto-HCT) has been evaluated as a consolidation treatment for acute myeloid leukemia (AML) in the 1980s and 1990s. (ovid.com)
  • A comparison was made also with allogeneic hematopoietic cell transplantation (allo-HCT). (ovid.com)
  • The results of conventional therapy are disappointing though autologous stem cell transplantation may improve survival. (haematologica.org)
  • High-dose therapy and stem cell transplantation is a treatment option for some myeloma patients. (myeloma.org.uk)
  • phase II trial is studying how well tandem (two) autologous stem cell transplantation works in treating patients with primary systemic (AL) amyloidosis. (bioportfolio.com)
  • Determine the tolerability of tandem autologous stem cell transplantation in patients with AL amyloidosis. (bioportfolio.com)
  • Peripheral Blood (PB) or Bone Marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation. (bioportfolio.com)
  • HERE ARE SEVERAL ABSTRACTS selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting clinical trials on autologous and allogeneic hematopoietic cell transplantation for various hematologic malignancies. (ascopost.com)
  • Additional selected abstracts on both autologous and allogeneic hematopoietic cell transplantation from the 2016 ASH Annual Meeting can be found online at http://www.ascopost.com. (ascopost.com)
  • Schmidtke B, Pflug N, Monsef I, Engert A, Skoetz N. High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia. (cochrane.org)
  • A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation. (biomedsearch.com)
  • Autologous peripheral hematopoietic stem cell transplantation (APHSCT) was performed to treat a patient with neuromyelitis optica. (biomedsearch.com)
  • OBJECTIVE To determine the safety and effects on insulin secretion of umbilical cord (UC) mesenchymal stromal cells (MSCs) plus autologous bone marrow mononuclear cell (aBM-MNC) stem cell transplantation (SCT) without immunotherapy in established type 1 diabetes (T1D). (diabetesjournals.org)
  • Promising results in the experimental and clinical settings support the use of stem cell transplantation (SCT) or bone marrow (BM)-derived hematopoietic stem cells (HSCs) for the treatment of autoimmune diabetes ( 5 - 10 ). (diabetesjournals.org)
  • NewYork-Presbyterian/Columbia is the first center in the New York metropolitan area to offer autologous islet cell transplantation. (columbiasurgery.org)
  • For several decades, physicians and researchers at NewYork-Presbyterian Hospital have been researching ways to treat type 1 diabetes by transplanting insulin-producing islet cells extracted from donor pancreata, a process known as allogeneic islet cell transplantation. (columbiasurgery.org)
  • In this procedure, called autologous islet cell transplantation, the patient's islet cells are extracted from the pancreas, specially processed, and reinfused into his or her liver. (columbiasurgery.org)
  • Autologous stem cell transplantation has been established as standard initial treatment for fit patients with symptomatic multiple myeloma. (cochrane.org)
  • During autologous stem cell transplantation, blood-forming stem cells are removed from the patient prior to intense chemotherapy and later given back to the same patient. (cochrane.org)
  • Since it is unclear whether autologous stem cell transplantation as initial treatment of multiple myeloma should be performed once or twice, we systematically searched for publications addressing the question whether the acute toxicity of autologous stem cell transplantation is counterbalanced by a long-term benefit for the patient. (cochrane.org)
  • Several studies in which patients undergoing one treatment with autologous stem cell transplantation were compared to patients undergoing autologous stem cell transplantation twice were identified. (cochrane.org)
  • The present Cochrane Review compares tandem autologous stem cell transplantation (TASCT) with single autologous stem cell transplantation (SASCT) as first-line treatment in patients with symptomatic MM with respect to overall survival (OS), event-free survival (EFS), quality of life (QoL) and treatment- or transplantation-related mortality. (cochrane.org)
  • Stem cell transplantation strategies are typically considered in the setting of ______________ indolent lymphoma. (mdedge.com)
  • Immune Profile after Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand? (frontiersin.org)
  • Pro-inflammatory Th1 and Th17 T cells are implicated as mediators of several human autoimmune conditions such as multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (aHSCT) has been tested in phase 2 clinical trials for MS patients with aggressive disease. (frontiersin.org)
  • Chemotherapy consisted of the sequential administration of high-dose cyclophosphamide (4 or 7 g/m 2 ) and granulocyte-colony stimulating factor (300 µg/day), followed by peripheral blood progenitor cell harvesting, administration of etoposide (2g/m 2 ) and methotrexate (8 g/m 2 only for Hodgkin's lymphoma) and autologous hematopoietic stem cell transplantation. (scielo.br)
  • Autologous bone marrow or stem cell transplantation has had an important role in the treatment of aggressive lymphoma for several decades. (ascopost.com)
  • Over the past 2 decades, numerous randomized studies demonstrated no improvement in overall survival when all patients received consolidative autologous bone marrow transplantation or stem cell transplantation (which has largely replaced bone marrow transplant). (ascopost.com)
  • It is very clear that the group of patients who might benefit from upfront consolidative autologous stem cell transplantation has decreased with every large randomized trial. (ascopost.com)
  • Thus, for younger, otherwise healthy patients with high-risk lymphoma, initial treatment with R-CHOP followed immediately by autologous stem cell transplantation seems a reasonable alternative. (ascopost.com)
  • In addition, recent studies have demonstrated that the results of salvage stem cell transplantation have changed since the PARMA trial. (ascopost.com)
  • In the postchemoimmunotherapy era, it appears that fewer than 50% of patients who were initially treated with R-CHOP, relapsed, and then had salvage therapy followed by stem cell transplantation have long-term survival. (ascopost.com)
  • In this context, a strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) has been explored to improve the prognosis of recurrent or high-risk brain tumors. (koreamed.org)
  • The authors report a series of seven patients (two of whom were seronegative) with severe myasthenia gravis treated with autologous hematopoietic stem cell transplantation. (aanem.org)
  • Hematopoietic stem cell transplantation offers a potential treatment option for patients in this group. (aanem.org)
  • It should be emphasized that this study is a retrospective case series, and that stem cell transplantation has not been studied in a prospective fashion in patients with myasthenia gravis. (aanem.org)
  • To investigate cytogenetic evolution after upfront autologous stem cell transplantation for newly diagnosed myeloma we retrospectively analyzed fluorescence in situ hybridization results of 128 patients with paired bone marrow samples from the time of primary diagnosis and at relapse. (haematologica.org)
  • We performed a retrospective analysis of 35 patients with primary diffuse large B-cell lymphoma of the mediastinum treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) plus autologous hematopoietic cell transplantation to determine outcome and prognostic features for progression-free survival (PFS). (bloodjournal.org)
  • Thirty-five patients with primary diffuse large B-cell lymphoma of the mediastinum in first response (complete remission [CR] or partial remission [PR]) with poor prognostic features, with primarily refractory disease, or with relapsed disease following conventional chemotherapy, were treated with CBV and autologous hematopoietic cell transplantation. (bloodjournal.org)
  • Patients with primary diffuse large B-cell lymphoma of the mediastinum can achieve prolonged PFS following high-dose chemotherapy and autologous hematopoietic cell transplantation. (bloodjournal.org)
  • Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment. (sigmaaldrich.com)
  • Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. (frontiersin.org)
  • Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan. (unboundmedicine.com)
  • Background and objectives Our study evaluated the efficiency and safety of autologous hematopoietic stem cell transplantation treatment for patients with refractory lupus nephritis. (asnjournals.org)
  • The major complications of stem cell transplantation were fever and gastrointestinal tract symptoms. (asnjournals.org)
  • Here, we present the first long-term endoscopic follow-up of a patient with Crohn disease undergoing autologous stem cell transplantation for haematological disease. (diva-portal.org)
  • She was initially treated with chemotherapy, and subsequently underwent autologous stem cell transplantation. (diva-portal.org)
  • This case suggests that autologous stem cell transplantation can change not only the clinical course, but also the natural history of intestinal inflammation in Crohn disease. (diva-portal.org)
  • Acute graft-versus-host disease (GVHD) is an immunologically mediated process, involving donor T cell responses to host alloantigens and the dysregulation of inflammatory cytokine cascade after allogeneic hematopoietic stem cell transplantation (allo-SCT) [ 1 - 3 ]. (termedia.pl)
  • She was randomized to a high risk stem cell transplantation group with a small remnant of neuroblastoma (partial response). (termedia.pl)
  • To carry out a phase I-II trial to elucidate the feasibility and efficacy of high dose cyclophosphamide (CY) supported by autologous peripheral blood stem cell transplantation (PBSCT) in the treatment of severe and refractory autoimmune disease (AD). (bmj.com)
  • Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. (aamds.org)
  • Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. (aamds.org)
  • The 4-year survival of the 65 patients randomized to autologous peripheral blood stem cell transplantation or a second consolidation course of high-dose cytarabine was 37% and 27%, respectively. (aamds.org)
  • Patients with a donor and candidates for allogeneic stem cell transplantation in first complete remission may have a better disease-free survival than those without a donor in case of myelodysplastic syndromes with intermediate/high-risk cytogenetics . (aamds.org)
  • Autologous peripheral blood stem cell transplantation does not provide longer survival than intensive chemotherapy. (aamds.org)
  • A treatment strategy of salvage chemotherapy and autologous stem cell transplantation in relapsed or refractory DLBCL patients on hemodialysis has not yet been established. (medworm.com)
  • We conducted a pharmacokinetic analysis in a refractory DLBCL patient with end-stage renal disease, and successfully administered adjusted dosing of salvage chemotherapies and conditioning regimen in autologous stem cell transplantation without any adverse events. (medworm.com)
  • On February 22, lenalidomide (Revlimid) was approved as maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplantation. (ascopost.com)
  • Lenalidomide (Revlimid) was approved as maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplantation. (ascopost.com)
  • Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/ refractory Hodgkin lymphoma (HL). (diva-portal.org)
  • 1. Oyama Y, Craig R, Traynor A E. et al Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. (pubmedcentralcanada.ca)
  • 3. Hinterberger W, Hinterberger‐Fischer M, Marmont A M. Clinically demonstrable anti‐autoimmunity mediated by allogeneic immune cells favourably affects outcomes after stem cell transplantation in human autoimmune disease. (pubmedcentralcanada.ca)
  • We matched 34 pairs of patients with regard to disease status at the time of autologous stem cell transplantation (auto-SCT). (springer.com)
  • Colpo A, Hochberg E, Chen YB (2012) Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. (springer.com)
  • Cortelazzo S, Rossi A, Viero P, Bellavita P, Marchioli R, Marfisi RM, Rambaldi A, Barbui T (1997) BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. (springer.com)
  • Autologous hematopoietic stem-cell transplantation was subsequently performed after induction chemotherapy. (uwi.edu)
  • Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. (lu.se)
  • Assessment of preterm cord blood cell characteristics and cytokine profiling of response to cell transplantation that may inform mechanisms of action of umbilical cord blood-derived cells and the design of future efficacy trials. (bmj.com)
  • Peripheral blood is a convenient source of stem cells for hematopoietic stem cell transplantation. (springer.com)
  • Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (harvard.edu)
  • Although the use of bortezomib alone and in combination with steroids has shown efficacy in AL amyloidosis, its role in combination with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) is unknown. (biomedcentral.com)
  • Surgical treatment includes arthroscopic drilling of intact lesions, securing of cartilage flap lesions with pins or screws, drilling and replacement of cartilage plugs, stem cell transplantation, and in very difficult situation in adults joint replacement. (wikipedia.org)
  • In autologous transplantation, the reinfused stem cells are derived from the patient's own bone marrow and collected from the peripheral blood. (renalandurologynews.com)
  • Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T et al (1994) Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. (springer.com)
  • Villa CH, Shore T, Van Besien K, Cushing M (2012) Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. (springer.com)
  • On the basis of this substantial body of pre-clinical data establishing the efficacy of SC transplantation into the central nervous system, and the merits of autologous preparations, a Phase 1 clinical trial was conducted to evaluate the safety and feasibility of ahSC transplantation into the injury epicenter of six subjects with subacute SCI. (genengnews.com)
  • The purpose of this study is to investigate the efficacy and safety of autologous transplantation of melanocytes in patients with vitiligo. (clinicaltrials.gov)
  • Laboratory and preclinical studies have provided evidence of the safety and potential efficacy of a strategy of intramyocardial transplantation of autologous CD34 + stem cells for neovascularization of chronically ischemic myocardium. (ahajournals.org)
  • This study evaluated the efficacy of xeno-free autologous cell-based treatment of limbal stem cell deficiency. (bmj.com)
  • There remains a paucity of information on the feasibility and safety of autologous UCBC transplantation in extremely premature infants. (bmj.com)
  • Our aim is to provide updated results on the worldwide use of autologous HSC transplantation (AHSCT) in T1D patients, to evaluate potential adverse events, and to explore the successes and potential pitfalls of this novel therapy. (diabetesjournals.org)
  • Conclusions This study confirms that AHSCT in selected patients with severe dcSSc results in sustained improvement of skin thickening and stabilizations of organ function up to 10 years after transplantation, so leading to a global clinical improvement, as showed by the persistent reduction in the ESSG clinical activity score. (bmj.com)
  • Outcomes are strongly correlated with disease status (first response v refractory v relapsed) at transplantation and chemotherapy responsiveness immediately before transplantation. (bloodjournal.org)
  • High-dose chemotherapy with autologous bone marrow transplantation (ABMT) has been successfully used in aggressive non-Hodgkin's lymphoma (NHL) as treatment intensification for patients with poor prognostic features and as salvage treatment for patients with refractory or relapsed disease following conventional chemotherapy. (bloodjournal.org)
  • Conclusions Autologous hematopoietic stem cell transplant could be used as a treatment option for refractory lupus nephritis, because it was relatively safe and associated with good outcomes. (asnjournals.org)
  • These observations suggest that high dose CY with autologous PBSCT is feasible and may be effective in the treatment of severe and refractory AD. (bmj.com)
  • Thirty patients with cisplatin-refractory germ cell tumor were treated with high-dose carboplatin, etoposide, and cyclophosphamide and autologous bone marrow transplantation. (aacrjournals.org)
  • Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. (springer.com)
  • Between 2 and 10 years after transplantation, 34% were insulin independent, with no grafts failing after 2 years. (nih.gov)
  • 2 years after transplantation). (nih.gov)
  • She has undergone ileo-colonoscopy with normal findings at 1, 2, 3 and 5 years after transplantation. (diva-portal.org)
  • CONCLUSIONS Functional goblet cells persist in autologous nasal mucosa for up to 10 years after transplantation. (bmj.com)
  • and the limited ability to use autologous stem cells to treat patients not in remission or with inherited nonmalignant lympho-hematopoietic diseases (Table I). (renalandurologynews.com)
  • Patients with plasma cell leukemia were more likely to enter complete remission after transplantation but their overall survival (25.7 months, 95% confidence interval 19.5-31.9 months) was inferior to that of patients with multiple myeloma (62.3 months, 95% confidence interval 60.4-64.3 months) ( P =0.000), due to the short duration of their post-transplant response and increased non-relapse-related mortality. (haematologica.org)
  • After a median follow-up of 72 (60-80) months, 18 (82%) patients achieved completed remission, one (5%) patient achieved partial remission, and one patient had no response and received peritoneal dialysis at 12 months after transplantation. (asnjournals.org)
  • Following transplantation, the patient has remained in clinical remission regarding both diseases, without anti-inflammatory medication. (diva-portal.org)
  • She is now doing well and is in complete remission 20 months after cord blood transplantation. (bioeticaweb.com)
  • A total of 652 children and adolescents with AML who achieved remission on 2 induction regimens using identical drugs and doses (standard and intensive timing) were eligible for allocation to allogeneic bone marrow transplantation (BMT) based on matched related donor status (n = 181) or randomization to autologous BMT (n = 177) or to aggressive high-dose cytarabine-based chemotherapy (n = 179). (uni-bonn.de)
  • The addition of RVD consolidation or a second autologous hematopoietic cell transplant was not superior to a single autologous hematopoietic cell transplant followed by lenalidomide maintenance in the upfront treatment of multiple myeloma. (ascopost.com)
  • Conclusions This largest study ever reported on plasma cell leukemia suggests that autologous transplantation can improve outcome, although results are markedly inferior to those achieved in patients with multiple myeloma, highlighting the need for novel approaches to this aggressive disorder. (haematologica.org)
  • A previous study whereby the median age of patients was 72 years old concluded that elderly multiple myeloma patients should not be excluded from transplantation displaying good results with melphalan 140 mg/m 2 (ref. 16 ). (nature.com)
  • The use of high dose immunosuppressive conditioning is essential to eliminate the autoimmune repertoire, and the re-infusion of autologous hematopoietic stem cells avoids long-term leucopenia by reconstitution of both immune and hematological systems. (rutgers.edu)
  • To address this issue, we compared outcome in 38 patients with low-grade lymphoma who received allogeneic BMT to 72 patients who underwent autologous BMT at our institution. (cancernetwork.com)
  • 1. Patients with diffuse large B cell non-Hodgkin's lymphoma who are 5-6 months status post an autologous stem cell transplant and are in CR. (knowcancer.com)
  • The analysis involved 106 classical Hodgkin's lymphoma patients who were consecutively submitted to high-dose chemotherapy followed by autologous transplants in a single institution from April 1993 to December 2006. (scielo.br)
  • Several published reports have suggested that although there is a lesser relapse rate for allogeneic bone marrow transplantation (BMT) compared to autologous BMT in patients with low-grade lymphoma, no survival advantage was evident because of higher toxicity associated with allogeneic BMT. (cancernetwork.com)
  • CONCLUSION: The data indicate a better outcome for allogeneic BMT vs autologous BMT for low-grade lymphoma, at a single institution. (cancernetwork.com)
  • This suggests that the subset of diffuse large B-cell lymphoma patients who experienced increased survival with R-CHOP were part of the group of patients who could be salvaged by autologous bone marrow transplantation in the CHOP era. (ascopost.com)
  • Thus, although autologous bone marrow transplantation might be the current recommended therapy for high-risk diffuse large B-cell lymphoma patients, we will likely see the development of novel targeted treatments that will also be studied in these patients. (ascopost.com)
  • Intensive chemoradiotherapy, with or without additional local radiotherapy, and unpurged autologous marrow transplantation was given to 68 patients with progressive non-Hodgkin's lymphoma. (uni-bonn.de)
  • Intensive chemoradiotherapy and autologous marrow transplantation produces durable remissions in some patients with progressive non-Hodgkin's lymphoma. (uni-bonn.de)
  • Conclusions- These favorable outcomes encourage future clinical trials of catheter-based, intramyocardial transplantation of autologous CD34+ MNCs in the setting of chronic myocardial ischemia. (ahajournals.org)
  • Here, we report an European Group for Blood and Marrow Transplantation (EBMT) registry study comparing presenting features and outcomes of 272 patients with primary PCL and 20844 patients with multiple myeloma undergoing autologous transplantation between 1980 and 2006. (haematologica.org)
  • Outcomes of autologous non-cultured melanocyte keratinocyte transplantation in vitiligo and nevus depigmentosus. (medworm.com)
  • As graft versus host disease (GVHD) rates are higher after unrelated donor transplantation, we examined whether there would be differences in transplant outcomes by graft type in children and adolesce. (bioportfolio.com)
  • Clonal hematopoiesis of indeterminate potential is associated with adverse outcomes following autologous hematopoietic cell transplant in patients with non-Hodgkin lymphomas (NHLs). (ascopost.com)
  • The transplantation outcomes of various conditioning regimens were compared. (unboundmedicine.com)
  • A total of 59% of individuals with T1D achieved insulin independence within the first 6 months after receiving conditioning immunosuppression therapy (with antithymocyte globulin and cyclophosphamide) and a single infusion of autologous HSCs, and 32% remained insulin independent at the last time point of their follow-up. (diabetesjournals.org)
  • The preparative regimen used was cyclophosphamide (Cytoxan, Neosar)/etoposide/total-body irradiation for patients in the autologous BMT group and for 22 patients (58%) in the allogeneic BMT group. (cancernetwork.com)
  • These cells do not cause graft-versus-host disease (GVHD), and thus, autologous transplantation is associated with less morbidity and mortality than is allogeneic bone marrow transplant (BMT) and increases the age limit and the number of patients who can undergo the procedure. (renalandurologynews.com)
  • Bone marrow transplantation in multiple sclerosis. (springer.com)
  • Read our guide to autologous stem cell transplants . (mskcc.org)
  • However, in autologous transplants, the harvest failure rates are high because of inadequate mobilization using G-CSF alone. (springer.com)
  • The relapse rates at 3 years in the allogeneic BMT and autologous BMT groups were 25% and 64%, respectively (P = .08). (cancernetwork.com)
  • Early CNS relapse carries a high risk of additional relapses, especially in the bone marrow, indicating the need for intensive systemic therapy, which may include hematopoietic stem cell (HSC) transplantation. (bioeticaweb.com)
  • In this context, intraarticular autologous fat transplantation for the treatment of osteoarthritis of the basal joint of the thumb as interposition arthroplasty would have deserved to be mentioned. (aerzteblatt.de)
  • Autologous fat injection versus lundborg resection arthroplasty for the treatment of trapeziometacarpal joint osteoarthritis. (aerzteblatt.de)
  • Prinja S, Kaur G, Malhotra P et al (2017) Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. (springer.com)
  • Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. (springer.com)
  • What is the role of tandem transplantation in the era of novel agents and where do patient-specific cytogenetics come into the equation when deciding on treatment? (nature.com)
  • We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. (nih.gov)
  • The two treatment groups were (1) autologous cartilage chips embedded in fibrin glue (ACC) (n = 12) and (2) marrow stimulation (MST) (n = 12). (nih.gov)
  • The issue for any patient is whether treatment with autologous transplantation will improve the chances of cure and whether an autologous or allogeneic transplant should be the therapy used to accomplish this. (renalandurologynews.com)
  • Comparative study between follicular unit transplantation with intact and unintact hair bulb in treatment for stable vitiligo. (medworm.com)
  • CONCLUSION: Single follicle transplantation was an alternative effective choice for treatment of vitiligo. (medworm.com)
  • transplantation may be effective treatment for primary systemic (AL) amyloidosis. (bioportfolio.com)
  • In 7 of 10 patients with treatment-related neoplasms, aberrant mutations were also detectable in the sample prior to autologous hematopoietic cell transplant. (ascopost.com)
  • Reporting of results of treatment- or transplantation-related mortality should clearly specify the type and number of events (the numerator) in a well-defined population (the denominator). (cochrane.org)
  • A favourable course of Crohn disease has been observed after allogeneic bone marrow transplantation, and there is now mounting evidence that autologous stem cell may be an effective treatment for severe autoimmune diseases. (diva-portal.org)
  • The results suggest that autologous transplantation of the ILM might contribute to a high closure rate of macular hole and be a preferable adjuvant to the treatment of large macular holes. (arvojournals.org)
  • Transplantation of autologous healthy conjunctiva of the fellow eye certainly represents the best treatment for these patients. (bmj.com)
  • In this first report of autologous cord blood transplantation for treatment of childhood leukemia, we discuss the safety and feasibility of this procedure as well as some of the uncertainties surrounding autologous cord blood collection and usage. (bioeticaweb.com)
  • In this report we describe a case of autologous cord blood transplantation for treatment of relapsed ALL and discuss the feasibility and safety of such a procedure. (bioeticaweb.com)
  • Due to the obvious lack of genetic disparity between donor and recipient, the existence of autologous GVHD (AGVHD) has been a topic of controversy [ 2 - 5 ]. (termedia.pl)
  • The estimated risk of knee donor-site morbidily following autologous osteochondral transplantation for osteochondral lesions of the talus was less than 10% and larger studies tended to report lower risk than smaller studies. (isakos.com)
  • Despite the promising clinical results of autologous osteochondral transplantation (AOT) for treating osteochondral lesions of the talus (OLT), the risk of knee donor-site morbidity (DSM) remains a cause of concern. (isakos.com)
  • Tandem bone marrow transplantation in multiple myeloma. (nih.gov)
  • tandem autologous transplant/lenalidomide maintenance vs autologous transplant/lenalidomide maintenance, P = .37). (ascopost.com)
  • Cumulative incidences of disease progression at 38 months were 42% (95% CI = 36%-48%), 42% (95% CI = 35%-48%), and 47% (95% CI = 40%-54%) for the autologous transplant/consolidation/ lenalidomide maintenance, tandem autologous transplant/lenalidomide maintenance, and autologous transplant/lenalidomide maintenance arms, respectively. (ascopost.com)
  • There were 39 cases of second primary malignancy reported in 36 participants, and the cumulative incidences for first second primary malignancy were 6.0% (95% CI = 3.4%-9.6%), 5.9% (95% CI = 3.3%-9.6%), and 4.0% (95% CI = 1.9%-7.2%) for autologous transplant/consolidation/lenalidomide maintenance, tandem autologous transplant/lenalidomide maintenance, and autologous transplant/lenalidomide maintenance, respectively. (ascopost.com)
  • Noncompliance rates following the first autologous hematopoietic cell transplant were 12%, 32%, and 5% for autologous transplant/consolidation/lenalidomide maintenance, tandem autologous transplant/lenalidomide maintenance, and autologous transplant/lenalidomide maintenance, respectively. (ascopost.com)
  • progression usually occurred less than 6 months after transplantation, most often at the sites of active disease before the transplant. (uni-bonn.de)
  • Background- We investigated whether catheter-based, intramyocardial transplantation of autologous endothelial progenitor cells can enhance neovascularization in myocardial ischemia. (ahajournals.org)
  • On univariate analysis, there was a survival advantage for allogeneic BMT compared to autologous BMT if there was bone marrow involvement (P = .003), if patients had three or fewer chemotherapy regimens (P = .007), low beta-2-microglobulin of £ 2 (P = .019), and normal LDH (P = .003). (cancernetwork.com)
  • If salvage bone marrow transplantation is effective, would consolidation bone marrow transplantation immediately after initial chemotherapy further improve the survival of advanced-stage, aggressive lymphomas? (ascopost.com)
  • According to data available so far, about one third of patients require no insulin therapy after autologous islet transplantation. (columbiasurgery.org)
  • In CALGB 100104, patients aged between 18 and 70 years who had undergone induction therapy followed by autologous stem cell transplant were eligible. (ascopost.com)
  • In the authors' opinion, the on-site preparation of the bone marrow cells within the operating theater eliminates the specific risk of ex vivo cell proliferation and has a safety advantage in the use of autologous cell therapy for bone regeneration. (pagepress.org)
  • Clinical tissue transplantation confirmed vessel patency and tissue viability for 1 week. (fraunhofer.de)
  • Clinical scores, T cell reconstitution, (antigen-specific) T cell cytokine production, and intracellular cytokine expression were determined following autologous BM transplantation (ABMT). (sigmaaldrich.com)
  • Current ongoing studies are investigating incorporating different agents such as daratumumab and lenalidomide before and after transplantation, respectively. (nature.com)
  • The current approval was based on findings in the Cancer and Leukemia Group B (CALGB) 100104 and Intergroupe Francophone du Myelome (IFM) 2005-02 randomized trials of lenalidomide maintenance vs placebo after autologous stem cell transplant. (ascopost.com)
  • After autologous stem cell transplant, lenalidomide maintenance can be started after adequate hematologic recovery (absolute neutrophil count ≥ 1,000/µL and/or platelet count ≥ 75,000/µL). (ascopost.com)
  • Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (springer.com)
  • Haas EM, Volkmer E, Giunta RE: Pilot study on the effects and benefits of autologous fat grafting in osteoarthritis of the CMC-1 joint compared to intraarticular cortisone injection: results after 3 months. (aerzteblatt.de)
  • Correcting Nasojugal Groove with Autologous Cultured Fibroblast Injection: A Pilot Study. (bioportfolio.com)
  • Conclusions- A randomized trial of intramyocardial injection of autologous CD34 + cells in patients with intractable angina was completed that provides evidence for feasibility, safety, and bioactivity. (ahajournals.org)
  • Autologous transplantation of 10 7 NA/CD31+ MNCs, 10 7 NA/CD31− MNCs, or PBS was performed with a NOGA mapping injection catheter to target ischemic myocardium. (ahajournals.org)
  • In the swine study, ischemic area by NOGA mapping, Rentrop grade angiographic collateral development, and echocardiographic left ventricular ejection fraction improved significantly 4 weeks after transplantation of NA/CD31+ MNCs but not after injection of NA/CD31− MNCs or PBS. (ahajournals.org)
  • When autologous islet transplantation is successful, the reinfused cells produce insulin, acting like a backup pancreas to regulate blood sugar. (columbiasurgery.org)
  • If the islet transplantation can prevent the onset of diabetes, that is an added bonus. (columbiasurgery.org)
  • Conclusions Autologous cultivated limbal epithelial transplantation using a xeno-free explant culture technique was effective in long-term restoration of corneal epithelial stability and improvement of vision in eyes with ocular surface burns. (bmj.com)